[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 676
1. Bavoux F, Elefant E: [Cancer and pregnancy: risks of exposure to cancer chemotherapy during pregnancy]. J Gynecol Obstet Biol Reprod (Paris); 2004 Feb;33(1 Suppl):S29-32
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cancer and pregnancy: risks of exposure to cancer chemotherapy during pregnancy].
  • [Transliterated title] Risques des médicaments.
  • Other toxic effects for the fetus and neonate (intrauterine exposure during second and third trimester) must be taken in consideration when prescribing chemotherapy for pregnant women.
  • Long-term studies are needed to evaluate the transplacental effects of chemotherapy during pregnancy; these studies should assess the child's mental and physical development, infertility and the occurrence of second malignancies.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Neoplasms / drug therapy. Pregnancy Complications, Neoplastic / drug therapy
  • [MeSH-minor] Abnormalities, Drug-Induced / etiology. Animals. Embryonic and Fetal Development / drug effects. Female. Humans. Infant, Newborn. Maternal-Fetal Exchange. Pregnancy. Risk Factors

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14968015.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 28
  •  go-up   go-down


2. Liu JH, Hsieh YY, Chen WS, Hsu YN, Chau GY, Teng HW, King KL, Lin TC, Tzeng CH, Lin JK: Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases. Int J Colorectal Dis; 2010 Oct;25(10):1243-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.
  • PURPOSE: Adjuvant systemic 5-fluorouracil (5-FU)-based chemotherapy improves survival after resection of synchronous colorectal liver metastases (CLMs), but not metachronous.
  • We retrospectively examined if adjuvant chemotherapy with new regimen containing oxaliplatin or irinotecan improved survivals after resection of metachronous CLMs.
  • METHODS: Between 2000 and 2007, 52 patients having undertaken resection of metachronous CLMs with curative intent were identified from Taipei Veterans General Hospital hospitalization registry.
  • Thirty-one patients experienced six to 12 cycles of FOLFOX or FOLFIRI chemotherapy while 19 patients with 5-FU/leucovorin (LV)-based chemotherapy following CLM resection.
  • The primary end point was disease-free survival (DFS) and secondary end point, overall survival (OS).
  • FOLFOX/FOLFIRI chemotherapy was shown by multivariate analyses to be an independent factor predicting a better DFS (hazard ratio [HR] = 0.37; 95% CI: 0.15-0.94; P = 0.036) and a better OS (HR = 0.27; 95% CI: 0.083-0.86, P = 0.026) than 5-FU/LV-based.
  • CONCLUSIONS: Adjuvant FOLFOX/FOLFIRI chemotherapy following resection of metachronous CLMs is demonstrated to have better DFS and OS than 5-FU/LV chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Colorectal Neoplasms / drug therapy. Liver Neoplasms / secondary. Organoplatinum Compounds / therapeutic use
  • [MeSH-minor] Aged. Female. Fluorouracil / therapeutic use. Humans. Leucovorin / therapeutic use. Male. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3109-16 [19451431.001]
  • [Cites] Int J Colorectal Dis. 2009 Apr;24(4):419-25 [19096855.001]
  • [Cites] Cancer Treat Rev. 2009 Dec;35(8):668-75 [19733977.001]
  • [Cites] J Surg Oncol. 2009 Dec 15;100(8):713-8 [19771561.001]
  • [Cites] J Clin Oncol. 2010 Feb 10;28(5):853-8 [20048179.001]
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2039-48 [10615075.001]
  • [Cites] Eur J Cancer. 1999 Sep;35(9):1343-7 [10658525.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] Surgery. 2001 Apr;129(4):408-13 [11283530.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1499-505 [11896097.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):759-66 [12035031.001]
  • [Cites] Br J Cancer. 2002 Aug 12;87(4):393-9 [12177775.001]
  • [Cites] Ann Surg. 2003 Dec;238(6):871-83; discussion 883-4 [14631224.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):229-37 [14657227.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1797-806 [15067028.001]
  • [Cites] Lancet. 1994 Jun 4;343(8910):1405-10 [7515134.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):59-71 [7740812.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):808-15 [9053508.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4553-60 [16002847.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4976-82 [17075115.001]
  • [Cites] Br J Cancer. 2007 Dec 17;97(12):1606-12 [18071347.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1007-16 [18358928.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4906-11 [18794541.001]
  • [Cites] Int J Colorectal Dis. 2009 Jan;24(1):83-6 [18766356.001]
  • [Cites] J Surg Oncol. 2009 Oct 1;100(5):349-57 [19572329.001]
  • (PMID = 20574727.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; Folfox protocol
  • [Other-IDs] NLM/ PMC2928445
  •  go-up   go-down


3. Iyoda A, Hiroshima K, Moriya Y, Iwadate Y, Takiguchi Y, Uno T, Nakatani Y, Yoshino I: Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma. J Thorac Cardiovasc Surg; 2009 Aug;138(2):446-53
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma.
  • In this study, we describe the clinical features of recurrent tumors of large-cell neuroendocrine carcinoma and discuss the role of adjuvant chemotherapy and management of recurrence in patients with large-cell neuroendocrine carcinoma.
  • METHODS: We retrospectively analyzed clinical data from 79 patients and evaluated the prognosis of patients with platinum-based adjuvant chemotherapy, recurrence patterns, patient response to chemotherapy or radiation therapy, and prognosis in patients who experienced relapse.
  • Patients who underwent platinum-based adjuvant chemotherapy had a significantly lower rate of tumor recurrence and a higher rate of disease-free survival than those who had non-platinum-based adjuvant chemotherapy or no adjuvant chemotherapy.
  • Multivariate analyses revealed that platinum-based adjuvant chemotherapy, pathologic stage, and the presence of second cancer are independent prognostic factors.
  • Three patients with limited resection of the primary tumor had poor prognosis with recurrence.
  • Postoperatively, 11 of the 36 patients without recurrence (30.6%) had metachronous second primary cancers, of which 4 patients had more than 1 site.
  • CONCLUSIONS: Patients with large-cell neuroendocrine carcinoma had frequent recurrence following resection of the primary tumor, and those without recurrence often developed metachronous second primary cancers.
  • Platinum-based adjuvant chemotherapy after surgery may be useful for preventing recurrence in patients with large-cell neuroendocrine carcinoma.
  • [MeSH-major] Carcinoma, Large Cell / drug therapy. Carcinoma, Neuroendocrine / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19619794.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Ng AK, Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC, Tarbell NJ, Stevenson MA, Friedberg JW, Mauch PM: Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood; 2002 Sep 15;100(6):1989-96
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors.
  • The excess risk of second malignancy after Hodgkin disease is an increasing problem.
  • In light of the long-term data, guidelines for follow-up of survivors of Hodgkin disease need to be redefined.
  • In this study we attempt to analyze the long-term risks and temporal trends, identify patient- and treatment-related risk factors, and determine the prognosis of patients who develop a second malignancy after radiation treatment with or without chemotherapy for Hodgkin disease.
  • Among 1319 patients with clinical stage I-IV Hodgkin disease, 181 second malignancies and 18 third malignancies were observed.
  • With a median follow-up of 12 years, the relative risk (RR) and absolute excess risk of second malignancy were 4.6 and 89.3/10 000 person-years.
  • The RR was significantly higher with combined chemotherapy and radiation therapy (6.1) than with radiation therapy alone (4.0, P =.015).
  • The risk increased with increasing radiation field size (P =.03) in patients who received combined modality therapy, and with time after Hodgkin disease.
  • After 15 and 20 years, there was a 2.3% and 4.0% excess risk of second malignancy per person per year.
  • The 5-year survival after development of a second malignancy was 38.1%, with the worst prognosis seen after acute leukemia and lung cancer.
  • The excess risk of second malignancy after Hodgkin disease continues to be increased after 15 to 20 years, and there does not appear to be a plateau.
  • Our analysis suggests that the risk may be reduced with smaller radiation fields, as are used in current trials of abbreviated chemotherapy and limited-field radiation therapy.
  • [MeSH-major] Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Combined Modality Therapy / adverse effects. Dose-Response Relationship, Radiation. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Risk. Risk Factors. Survival Rate

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12200357.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


5. Fouladi M, Gururangan S, Moghrabi A, Phillips P, Gronewold L, Wallace D, Sanford RA, Gajjar A, Kun LE, Heideman R: Carboplatin-based primary chemotherapy for infants and young children with CNS tumors. Cancer; 2009 Jul 15;115(14):3243-53
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin-based primary chemotherapy for infants and young children with CNS tumors.
  • BACKGROUND: A carboplatin-based chemotherapy regimen was used as primary postoperative therapy in infants with central nervous system (CNS) tumors to limit renal and ototoxicity and to target systemic exposure.
  • METHODS: Fifty-three patients aged <age 3 years with embryonal CNS tumor medulloblastoma (n = 20), ependymoma (EP, n = 21), choroid plexus carcinoma (CPCA, n = 5), and primitive embryonal neoplasms including atypical teratoid rhabdoid tumors (n = 7) were treated with cyclophosphamide, etoposide, and carboplatin.
  • Radiation therapy was used only for residual disease at the end of chemotherapy or disease progression.
  • RESULTS: The response rate after 2 cycles of chemotherapy was 34% (complete response, 13.8%; partial response, 20.7%).
  • For medulloblastoma, the 5-year PFS was 26% +/- 9%; for EP it was 33% +/- 10%; for CPCA it was 80% +/- 18%; and for primitive neuroectodermal and atypical teratoid rhabdoid tumors it was 0%.
  • Two patients developed late second malignancies; 1 was associated with germline p53 mutation.
  • Five-year survival data are comparable to those reported in other recent studies, including high-dose chemotherapy studies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Central Nervous System Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Humans. Infant. Survival Analysis. Time Factors. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19484793.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / P30 CA021765-30; United States / NCI NIH HHS / CA / R25 CA023944; United States / NCI NIH HHS / CA / CA21765
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ NIHMS124374; NLM/ PMC4307774
  •  go-up   go-down


6. las Heras Alonso MM, Gelabert Mas A: [Independent multiple primary tumors and second primary neoplasms. Relationship between smoking]. Actas Urol Esp; 2010 Jun;34(6):516-21
MedlinePlus Health Information. consumer health - Smoking.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Independent multiple primary tumors and second primary neoplasms. Relationship between smoking].
  • [Transliterated title] Tumores primarios múltiples independientes y segundas neoplasias primarias. Relación con el hábito de fumar.
  • Multiple primary tumors and second primary neoplasms have been increasing in incidence in recent decades and are reviewed in this paper.
  • The reasons attributed to this significant increase are fundamentalment the best diagnosis of multiple concurrent cases and increased overall survival of patients diagnosed with cancer, allowing surface new primary tumors in other organs during or after standard monitoring.
  • At the same time are invoked as possible causes of the widespread use of radio and chemotherapy for the first tumor.
  • The genitourinary system is frequently involved in cases of multiple neoplasms; urological organs are one of the few settlement sites of primary tumors in almost a quarter of cases.
  • This suggests a susceptibility/genitourinary system increased target for neoplastic disease.
  • We believe that the concept of clinical monitoring of this subset of patients should be revised, and should entail a screening of the most common second primary neoplasms since the risk of developing a subsequent independent cancer after presenting a urothelial tumor is considerably increased.
  • [MeSH-major] Neoplasms, Multiple Primary / etiology. Neoplasms, Second Primary / etiology. Smoking / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20510114.001).
  • [ISSN] 1699-7980
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 26
  •  go-up   go-down


7. Adam R, Bhangui P, Poston G, Mirza D, Nuzzo G, Barroso E, Ijzermans J, Hubert C, Ruers T, Capussotti L, Ouellet JF, Laurent C, Cugat E, Colombo PE, Milicevic M: Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg; 2010 Nov;252(5):774-87
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases?
  • BACKGROUND: Chemotherapy is increasingly used in colorectal liver metastases (CRLMs) even when they are initially resectable.
  • The aim of our study was to address the still pending question of whether perioperative chemotherapy is really beneficial in patients developing solitary metastases at a distance from surgery of the primary.
  • METHODS: We analyzed a multicentric cohort of 1471 patients resected for solitary, metachronous, primarily resectable CRLMs without extrahepatic disease in the LiverMetSurvey International Registry over a 15-year period.
  • Patients who received at least 3 cycles of oxaliplatin- or irinotecan-based chemotherapy before liver surgery (group CS, n = 169) were compared with those who were resected upfront (group S, n = 1302).
  • RESULTS: Patients of group CS were more frequently females (49% vs 36%, P = 0.001) and had larger metastases (≥5 cm, 33% vs 23%, P = 0.007); no difference was observed with regard to age, site of the primary tumour, time delay to occurrence of metastases, and carcinoembryonic antigen (CEA) levels at the time of diagnosis in the 2 groups.
  • At univariate analysis, preoperative chemotherapy did not impact the overall survival (OS) (60% at 5 years in both groups); however, postoperative chemotherapy was associated with better OS (65% vs 55% at 5 years, P < 0.01).
  • At multivariate analysis, age 70 years or older (P = 0.05), lymph node positivity in the primary tumor (P = 0.02), a primary-to-metastases time delay of less than 12 months (P = 0.04), raised CEA levels of more than 5 ng/mL at diagnosis (P < 0.01), a tumor diameter of 5 cm or more (P < 0.01), noncurative liver resection (P < 0.01), and the absence of postoperative chemotherapy (P < 0.01) were independent prognostic factors of survival.
  • The disease-free survival (DFS) was negatively influenced by CEA level of more than 5 ng/mL (P < 0.01), size of the metastases 5 cm or more (P = 0.05), and the absence of postoperative chemotherapy (P < 0.01).
  • When patients with metastases of less than 5 cm in size were compared to those with metastases of size 5 cm or more, preoperative chemotherapy did not influence the OS or DFS in either group.
  • Postoperative chemotherapy, on the other hand, improved OS and DFS in patients with metastases of size 5 cm or more but not in patients with metastases of less than 5 cm in size.
  • CONCLUSIONS: Although preoperative chemotherapy does not seem to benefit the outcome of patients with solitary, metachronous CRLM, postoperative chemotherapy is associated with better OS and DFS, mainly when the tumor diameter exceeds 5 cm.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / surgery
  • [MeSH-minor] Aged. Biomarkers / analysis. Carcinoembryonic Antigen / analysis. Chi-Square Distribution. Combined Modality Therapy. Female. Hepatectomy. Humans. Male. Postoperative Complications. Prognosis. Proportional Hazards Models. Registries. Survival Rate

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21037433.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


8. Conti F, Vici P: [Chemotherapy in the treatment of breast carcinoma]. Tumori; 2003 Jul-Aug;89(4 Suppl):181-2
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy in the treatment of breast carcinoma].
  • [Transliterated title] La chemioterapia nel trattamento del carcinoma mammario.
  • Breast cancer (BC) is the most common malignancy and the second most common cause of cancer-related death in Western European and North American women.
  • Neoadjuvant chemotherapy may be used in the management of both BC patients with locally advanced disease, and those with earlier stage and operable tumors.
  • Data from recently phase III trials and worldwide consensus conference document the benefit of adjuvant chemotherapy in improving disease free survival and overall survival for patients diagnosed with invasive BC > 1 cm.
  • When BC cells metastasize to distant organs, the disease is incurable, but chemotherapy may offer these patients a significant palliation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Chemotherapy, Adjuvant. Clinical Trials, Phase III as Topic. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Neoadjuvant Therapy. Palliative Care. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12903586.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  • [Number-of-references] 2
  •  go-up   go-down


9. Kubota M, Lin YW, Hamahata K, Sawada M, Koishi S, Hirota H, Wakazono Y: Cancer chemotherapy and somatic cell mutation. Mutat Res; 2000 Oct 31;470(2):93-102
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer chemotherapy and somatic cell mutation.
  • The occurrence of a second neoplasm is one of the major obstacles in cancer chemotherapy.
  • The elucidation of the genotoxic effects induced by anti-cancer drugs is considered to be helpful in identifying the degree of cancer risk.
  • Numerous investigations on cancer patients after chemotherapy have demonstrated: (i) an increase in the in vivo somatic cell mutant frequency (Mf) at three genetic loci, including hypoxanthine-guanine phosphoribosyl-transferase (hprt), glycophorin A (GPA), and the T-cell receptor (TCR), and (ii) alterations in the mutational spectra of hprt mutants.
  • However, the time required for and the degree of such changes are quite variable among patients even if they have received the same chemotherapy, suggesting the existence of underlying genetic factor(s).
  • Accordingly, some cancer patients prior to chemotherapy as well as patients with cancer-prone syndrome have been found to show an elevated Mf.
  • Based on the information obtained from somatic cell mutation assays, an individualized chemotherapy should be considered in order to minimize the risk of a second neoplasm.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Mutation. Neoplasms / drug therapy
  • [MeSH-minor] Humans. Neoplasms, Second Primary / chemically induced. Neoplasms, Second Primary / genetics

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11027962.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] NETHERLANDS
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 68
  •  go-up   go-down


10. Aung L, Gorlick R, Healey JH, Shi W, Thaler HT, Shorter NA, Huvos AG, Meyers PA: Metachronous skeletal osteosarcoma in patients treated with adjuvant and neoadjuvant chemotherapy for nonmetastatic osteosarcoma. J Clin Oncol; 2003 Jan 15;21(2):342-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous skeletal osteosarcoma in patients treated with adjuvant and neoadjuvant chemotherapy for nonmetastatic osteosarcoma.
  • PURPOSE: The prognosis for patients who develop metachronous skeletal osteosarcoma (OS) has been considered grave compared with that for patients with relapse limited to the lungs.
  • We investigated the incidence and outcome of metachronous skeletal OS after initial treatment of the primary tumor.
  • PATIENTS AND METHODS: Twenty-three (median age 18.7 years) of 426 patients with nonmetastatic, high-grade primary OS treated at Memorial Sloan-Kettering Cancer Center (New York, NY) between February 1973 and May 2000 developed metachronous skeletal OS.
  • Initial therapy included combination chemotherapy and surgery.
  • Treatment of subsequent relapses consisted of chemotherapy or radiation alone or surgery with or without additional individualized chemotherapy.
  • RESULTS: The median time from the diagnosis of primary OS to the development of metachronous OS was 1.4 years (range, 0.2 to 11.3 years).
  • At last follow-up (range, 0.1 to 12.8 years), five (30.4%) patients were alive with no evidence of disease (range, 1.7 to 12.8 years; median, 4.4 years).
  • For 11 patients who developed metachronous OS 24 months or more from initial diagnosis, 5-year postmetachronous survival rate for patients receiving combined modality versus monotherapy was 83% (95% CI, 54% to 100%) and 40% (95% CI, 0% to 83%), respectively.
  • CONCLUSION: In a small subset of patients who developed late metachronous OS, combined-modality therapy with surgery and aggressive chemotherapy may result in long-term postmetachronous survival.
  • This implies that principles used in treatment of primary OS may be applied to patients with late metachronous skeletal OS.
  • [MeSH-major] Bone Neoplasms / drug therapy. Neoplasms, Second Primary / etiology. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Incidence. Male. Neoadjuvant Therapy. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2004 Apr 15;22(8):1524 [15084629.001]
  • (PMID = 12525528.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Chronowski GM, Wilder RB, Levy LB, Atkinson EN, Ha CS, Hagemeister FB, Barista I, Rodriguez MA, Sarris AH, Hess MA, Cabanillas F, Cox JD: Second malignancies after chemotherapy and radiotherapy for Hodgkin disease. Am J Clin Oncol; 2004 Feb;27(1):73-80
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancies after chemotherapy and radiotherapy for Hodgkin disease.
  • The purpose of this preliminary study was to determine the incidence of second malignancies after combined-modality therapy for adults with Hodgkin disease and relate it to the details of initial treatment.
  • We retrospectively studied 286 patients ranging in age from 16 to 88 years with stage I or II Hodgkin disease who were treated between 1980 and 1995 with chemotherapy followed 3 to 4 weeks later by radiotherapy.
  • Patients received a median of three cycles of induction chemotherapy.
  • The median radiotherapy dose was 40 Gy given in 20 daily 2-Gy fractions.
  • In an effort to reduce the risk of second malignancies, we have stopped using the alkylating agents nitrogen mustard and procarbazine and elective paraaortic and splenic radiotherapy after chemotherapy.
  • [MeSH-major] Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Dose Fractionation. Female. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / adverse effects. Prednisone / administration & dosage. Prednisone / adverse effects. Retrospective Studies. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vincristine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14758137.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16672; United States / NCI NIH HHS / CA / CA 6294
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone; NOVP protocol
  •  go-up   go-down


12. Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M, Picci P: Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer; 2005 Dec;41(18):2836-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy.
  • Around 1148 patients with non-metastatic osteosarcoma of the extremity were treated in a single institution between 1972 and 1999 with 4 different protocol of adjuvant and 7 different protocols of neoadjuvant chemotherapy.
  • The 10-year EFS and OS were 52% and 57%, respectively, and the results significantly correlated with serum alkaline phosphatase levels; the type of chemotherapy (adjuvant vs neoadjuvant); and with histologic response to pre-operative treatment.
  • Aggressive chemotherapy and surgery could cure about the 60% of patients with osteosarcoma of the extremity.
  • However, since local or systemic relapses, myocardiopathies and a second malignancy are possible even 5 or more years since the beginning of treatment, a long-term follow-up is recommended.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Extremities. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasms, Second Primary / drug therapy. Postoperative Complications / etiology. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16298125.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


13. Matsuoka H, Maeda K, Hanai T, Sato H, Masumori K, Koide Y, Katsuno H, Agata T, Noro T, Honda K, Shiota M, Ozeki S, Hatta K, Morise Z, Sugioka A, Ota H: [HAI chemotherapy for liver metastases of colorectal cancer]. Gan To Kagaku Ryoho; 2010 Jul;37(7):1303-6
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [HAI chemotherapy for liver metastases of colorectal cancer].
  • We evaluated the effect of hepatic arterial infusion(HAI)chemotherapy for liver metastases from colorectal cancer.
  • A total of 65 patients received HAI chemotherapy.
  • The chemotherapy regimen consisted of weekly 5-FU (1, 500 mg/body) or 5-FU (400 mg/mm2) and l-LV (200mg/mm2).
  • Median survival time with HAI chemotherapy was 13.
  • There was no evidence of myelosuppression, and HAI could be continued for a long time even for poor PS patients.
  • There were no differences in survival time between synchronous, metachronous and postoperative metachronous liver metastases.
  • In the patients who underwent curative hepatectomy after HAI chemotherapy, the 5-year survival rate was 21%, which was better than in patients with HAI chemotherapy alone.
  • HAI chemotherapy could thus be an option for unresectable liver metastases, which could be well tolerated.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Colorectal Neoplasms / drug therapy. Fluorouracil / therapeutic use. Leucovorin / therapeutic use. Liver Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647714.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Ghielmini ME, Hsu Schmitz S, Martinelli G, Peccatori F, Hess U, Fey M, Zucca E, Stahel R, Ketterer N, Cerny T: Long-term follow-up of patients with follicular lymphoma (FL) receiving single agent rituximab at two different schedules in study SAKK 35/98. J Clin Oncol; 2009 May 20;27(15_suppl):8512

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some patients respond to this treatment for a prolonged time, so we investigated, in a clinical trial, the proportion of long-term responders and the characteristics predicting long-term response.
  • METHODS: Between 1998 and 2002, chemotherapy naïve (n = 64) or pre-treated (n = 138) FL patients received 4 weekly doses of rituximab: those responding or with stable disease were randomized to either no further treatment (observation, n = 78) or 4 additional doses of rituximab given at 2 months intervals (consolidation, n = 73).
  • RESULTS: At a median follow up of 8.9 years, and with all living patients having been followed for at least 5 years, the median event-free survival (EFS: time until progression, relapse, second tumor or death) is 13 months for the observation and 24 months for the consolidation arm (p=0.0012).
  • The only significant prognostic factor for EFS in a multivariate Cox regression was having received consolidation rituximab (hazard ratio = 0.58, CI = 0.44-0.87, p = 0.008), whereas being chemotherapy naïve, presenting with stage < IV and showing a VV phenotype at position 158 of the Fc receptor RIIIA were not any more significantly prognostic in this long term analysis, in contrast to previous data with shorter follow-up.
  • No long-term toxicity from treatment was observed.
  • There were 21 cases of second malignancy: 11 on observation, 10 receiving the consolidation arm.
  • CONCLUSIONS: It appears that the EFS advantage of prolonged versus short course rituximab continues for many years after the end of treatment.
  • This seems to hold true independently from previous treatment, stage or 158-phenotype of the Fc receptor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960877.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Saigí E, Musulén E, García-García Y, Bombardó J, Nogué M, Seguí MA, Fernández-Morales L, Martinez-Peralta S, Rey M, Pericay C: Study of survival in non metastatic surgical colon cancer. J Clin Oncol; 2004 Jul 15;22(14_suppl):3750

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3750 Background: Colon cancer is the second neoplasm in men and women.
  • The treatment seems to improve the survival.
  • 70 patients were metastatic at the time of diagnosis or behind surgery (5 months).
  • The prognosis factors were: age at diagnosis, gender, locations in the large bowel, kind of surgery, pT, pN, stage, use of chemotherapy, disease free survival (DFS) and overall survival (OS).
  • 145 patients received adjuvant chemotherapy.
  • Patients with pT4 or pN2 should received aggressive treatments for the high risk of metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014094.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Hill-Kayser CE, Vachani C, Hampshire MK, Jacobs LA, Metz JM: Utilization of Internet-based survivorship care plans by survivors of gynecologic cancers. J Clin Oncol; 2009 May 20;27(15_suppl):5592

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 5592 Background: Survivors of gynecologic cancers may be at risk for cancer-related late-effects, including fatigue, pain, second malignancy risk, and sexual side effects.
  • Users responding to 17 queries regarding demographics, diagnosis, and treatment receive comprehensive, individualized guidelines for future care.
  • Surgery was undergone by 98% of ovarian, 97% of endometrial, and 81% of cervical cancer survivors, and chemotherapy/ radiotherapy by 91%/12%, 51%/59%, and 67%/67%, respectively.
  • Of all gynecologic cancer survivors, 53% reported being followed by an oncologist, 14% a primary care provider (PCP), and 27% both.
  • CONCLUSIONS: Most survivors of gynecologic malignancies have undergone multimodality treatment and may particularly benefit from SCP guidelines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962396.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Ayan I, Kebudi R, Ozger H, Yaman Agaoglu F, Gorgun O, Bilgic B, Eralp L, Dizdar Y, Darendeliler E: Childhood osteosarcoma: Evaluation of 94 cases. A single institution study. J Clin Oncol; 2009 May 20;27(15_suppl):10040

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 10040 Background: Osteosarcoma is the most frequent bone tumor in children and adolescents.
  • The aim of this study is to evaluate the demographic characteristics, therapy, and long term outcome of children with osteosarcoma in a single institution.
  • METHODS: Between January 1990 and December 2006, 94 children (53 male, 41 female) with a median age of 13 (5-16) years and a histopathologic diagnosis of osteosarcoma were treated with an institutional chemotherapy regimen comprising of 6 courses (3 pre-, 3 postoperatively) of epirubicin (90 mg/m2), cisplatin(100 mg/m2), and ifosfamide(2 g/m2 × 3 days) every 3 weeks.
  • RESULTS: The median follow-up time was 36 (2-219) months.
  • 68 patients were alive at the time of analysis.
  • 26 patients died; 20 of disease, 5 of toxicity, and 1 of second malignancy (acute myeloid leukemia).
  • 5 and 10 year EFS for nonmetastatic patients was superior to those with metastatic disease [62.4 % (95% CI 49.9-79.9 %) vs. 6.9 % (95% CI 0-19.9 %)) (p<0.001).
  • 10 year OS for 18 patients (11 metastatic at diagnosis) who progressed during preoperative chemotherapy was 13 % vs. 75 % for those who didnot have progressive disease (p< 0.001).
  • The rate of histologically good response to preoperative chemotherapy was 64.5 %.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962466.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Marinaccio M, Mele E, Poma S, Cantinieri C, Cocca M, Latiano T: Pretreatment normalization of mild anemia with epoetin alfa predicts long-term outcome for women with epithelial ovarian cancer. J Clin Oncol; 2004 Jul 15;22(14_suppl):5132

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this larger trial was to understand better the influence of recombinant human erythropoietin (rHuEPO) on the outcome of ovarian cancer patients showing anemia before undergoing surgery and chemotherapy.
  • METHODS: Between 1999 and 2003, 42 patients with mild anemia (Hgb 10.6-11.9 g/dL) secondary to advanced epithelial ovarian cancer were randomized to receive epoetin alfa (21 pts.) or not (21 pts.) before primary surgery.
  • All patients were without past or present second malignancy and aged less than 76 years.
  • After surgery all patients underwent adjuvant chemotherapy with paclitaxel (175mg/mq) plus carboplatin (AUC5).
  • Patients in the treatment group were administered rHuEPO, 10.000 IU, three times a week subcutaneously for 4-6 weeks.
  • The relationship of Hgb to survival was determined by Cox Regression analysis after adjusting for the effect of known prognostic variables including FIGO stage, tumor grade and residual tumor.
  • The median relapse-free survival time was found to be 26 months in patients treated with rHuEPO and 18 months in the control arm; the evaluation of median survival time is in progress, however Kaplan-Meier 12-month estimates of survival were 65% for the rHuEPO arm and 50 % for the control arm, revealing a trend in overall survival favoring normalization of pre-treatment anemia with rHuEPO (Kaplan-Meier analysis p=0.12, Cox regression analysis p=0.044).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016754.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Sirop S, Saha S, Soni M, Chkravarty B, Korant A, Dutt N, Wilson D, Ng P, Arora M, Singh T: A second peritoneal cytology instead of the initial cytology as a prognostic factor in epithelial ovarian cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16572

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A second peritoneal cytology instead of the initial cytology as a prognostic factor in epithelial ovarian cancer.
  • : e16572 Background: Ovarian cancer (OvCa) is the most common gynecological malignancy causing death.
  • The role of a repeat peritoneal washing after resection of the tumor at the time of surgery has not been evaluated in the past.
  • All pts underwent debulking surgery with two peritoneal washings during surgery: one before and one after resection of the tumor.
  • The primary outcome was overall survival.
  • Exclusion criteria included second malignancy, refusal of chemotherapy, or non-surgical candidates.
  • Of these, 8 (gp A) had both peritoneal washings +ve for malignancy, 16 (gp B) had the first washing +ve and the second one negative (-ve) for malignancy, and 19 (gp C) had both washings -ve for malignancy.
  • There was no significant difference in the demographics and grade of disease (Table).
  • The median length of stay was 13.2, 10.9, 9 days and the median CA 125 level at the time of diagnosis was 651, 440 and 445 in gp A, B and C respectively.
  • The percentage of pts with persistent or recurrent disease was 62.5%, 41.7%, and 36.4% in gpA, B and C respectively.
  • CONCLUSIONS: While preliminary, our study shows that at the time of debulking surgery of OvCa, a -ve peritoneal washing after resection of the tumor following an initial +ve washing is a possible independent prognostic factor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961509.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Piura E, Chapman JW, Lipton A, Zhu L, Leitzel K, Wilson CF, Pritchard KI, Shepherd L, Pollak MN: Serum 1-OH vitamin D (D) and prognosis of postmenopausal breast cancer (BC) patients: NCIC-CTG MA14 trial. J Clin Oncol; 2009 May 20;27(15_suppl):534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We previously found that the baseline serum bone resorption marker, beta C-terminal telopeptides of type I collagen (B-CTx), was associated with bone-only first relapse, and that higher levels of insulin secretion as estimated by c-peptide level was associated with reduced event-free survival (EFS).
  • Stratification was by adjuvant chemotherapy, axillary lymph node status, and hormone receptor status.
  • EFS, time from randomization to recurrence, second malignancy, or death due to any cause, was the primary endpoint.
  • Recurrence-free survival (RFS), time from randomization to recurrence of the primary disease alone, was a secondary endpoint.
  • Continuous D was not associated with RFS of any relapse (p = 0.57), bone only relapse (p = 0.19), bone + other site of relapse (p = 0.73), or all bone relapse types (p = 0.66).
  • CONCLUSIONS: D was not associated with EFS or RFS in postmenopausal breast cancer patients in this well controlled hormonal therapy study, a result consistent with some, but not all, studies of this issue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960688.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Schoeler D, Lindner T, Schulenburg S, Von der, Pink D, Reichardt P: Coincidence of retinoblastoma and leiomyosarcoma in father and daughter - a rare case report. J Clin Oncol; 2004 Jul 15;22(14_suppl):9059

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 9059 Retinoblastoma is the most common primary ocular malignancy of childhood, which results from sporadic or heritable mutations in the retinoblastoma gene, RB1.
  • It is well recognized to occur in two patterns: a sporadic, non-heritable form and a genetic, heritable form presenting with uni- or bilateral disease, which is assaociated with a germline defect and greatly elevated risk of developing a second malignancy.
  • Father: The 54-years old male was diagnosed with unilateral retinoblastoma of his right eye in 1950 and underwent enucleation in the age of 1, he was not treated by chemotherapy or radiation in the childhood.
  • He was treated by polychemotherapy, radiotherapy and surgery of lung and soft tissue metastases.
  • At the moment the patient is treated by a fourth line chemotherapy with ET-743.
  • She underwent a chemotherapy with epirubicin/ifosfamide followed by surgery.
  • The second local recurrence of leiomyosarcoma in 2000 was treated by stereotactic radiotherapy.
  • Since that time the situation remains stable.
  • CONCLUSIONS: The propensity for survivors of heritable retinoblastoma to develop second nonocular malignancies is well known, they can occur within the field of irradiation (case of the daughter) or fail previous radiation or chemotherapy (case of the father).
  • In the presented family the grandchild is also affected by retinoblastoma, fortunately it is under local control by laser therapy.
  • With this familial history systematic screening for tumor symptoms should be performed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014098.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Garcia Del Muro X, Maroto P, Gumá J, López Brea M, Sastre J, Arranz JA, Lainez N, López Lara F, Berenguer G, Germá-Lluch JR: Chemotherapy as an alternative to radiotherapy in the treatment of stages IIA/B testicular seminoma: A Spanish Germ Cell Cancer Group study. J Clin Oncol; 2004 Jul 15;22(14_suppl):4530

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy as an alternative to radiotherapy in the treatment of stages IIA/B testicular seminoma: A Spanish Germ Cell Cancer Group study.
  • : 4530 Background: Radiotherapy (RT) is considered the standard treatment for stages IIA/B testicular seminoma.
  • However, RT has been associated with an increased incidence of second malignancies in long-term survivors.
  • As chemotherapy (CT) is highly effective in advanced disease and in recurrences after RT, we have developed a multicenter prospective protocol of treatment with CT in patients (pts) with stages IIA/B seminoma.
  • METHODS: We studied 71 consecutive pts with stages IIA and IIB testicular seminoma, initially treated with cisplatin-based chemotherapy, from April 1994 to March 2003 in 26 centers.
  • The treatment administered was: EP (etoposide, cisplatin) in 62 and BEP (bleomycin, etoposide, cisplatin) in 9 pts.
  • Our results support the role of CT as an alternative to RT in the treatment of these pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016062.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Roussel M: Non-Hodgkin's lymphoma in women with breast cancer: A retrospective study of 46 patients. J Clin Oncol; 2004 Jul 15;22(14_suppl):6670

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Improvement in screening and treatment strategies increased long-term survivors.
  • Those women are then at risk for second malignancies, including non-Hodgkin lymphoma (NHL).
  • Currently, no genetic or treatment-related risk factors have been demonstrated.
  • In the Curie's Institute cohort of BC, we analyzed women with second NHL and tried to assess risk factors.
  • 78.3% received radiotherapy and 41.3% systemic therapy.
  • All pts received appropriate treatments.
  • A 3/1 case control study matched on age, date of BC diagnosis and survival didn't show treatment-related risk factor.
  • CONCLUSION: NHL is a second primary malignancy in women with breast cancer.
  • There is no evidence in our cohort for treatment-induced NHL.
  • [Figure: see text] S: surgery, RTE: external radiotherapy, CT: chemotherapy, H: hormonotherapy No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016450.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Campos A, Costa NM, Vaz CP, Carvalhais A, Roncon S, Campilho F, Pimentel P: Secondary malignancies after stem cell transplantation. J Clin Oncol; 2004 Jul 15;22(14_suppl):6651

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary malignancies after stem cell transplantation.
  • : 6651 Background: Several reports have suggested that patients who undergo stem cell transplantation (SCT) are at increased risk of developing therapy-related secondary malignancies because of several risk factors, including malignant primary disease, conditioning with radiation and/or chemotherapy, and graft-versus-host disease (GVHD).
  • Twelve post-transplant malignancies were identified in 10 patients (11 after autologous and 1 after allogeneic SCT), 7 male and 4 female, with a median age of 32 years (range: 1-55).
  • RESULTS: At 10 years the actuarial probability of a second neoplasm after SCT was 6.0% (± 2.5%), being 3.2% (± 3.2%) for allogeneic, and 8.0% (± 3.5%) for autologous SCT.
  • The mean follow-up time was 29 months (± 1.3).
  • The median time from SCT to diagnosis of second neoplasm was 10.5 months (range: 2.96-71.5), and overall survival at 10 years was 40% (± 17%).
  • The patient characteristics with secondary malignancies after autologous SCT are listed in table 1.
  • The remaining patient, a man with primary diagnosis of acute myeloid leukaemia M5, underwent allogeneic SCT conditioned with busulfan and cyclophosphamide.
  • He developed a late severe chronic GVHD with mouth involvement, being treated mainly with cyclosporine and prednisone.
  • CONCLUSIONS: We found a low incidence of secondary malignancies after allogeneic SCT.
  • The follow-up time is necessarily insufficient for allogeneic SCT.
  • There is a trend between autologous SCT for Hodgkin disease and secondary myelodysplastic syndrome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016395.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff D, Kuderer NM, Lambert K, Crawford J: Acute myeloid leukemia or myelodysplastic syndrome (AML/MDS) and overall mortality with chemotherapy (CT) and granulocyte colony-stimulating factor (G-CSF): A meta-analysis of randomized controlled trials (RCTs). J Clin Oncol; 2009 May 20;27(15_suppl):9524

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia or myelodysplastic syndrome (AML/MDS) and overall mortality with chemotherapy (CT) and granulocyte colony-stimulating factor (G-CSF): A meta-analysis of randomized controlled trials (RCTs).
  • Eligibility included RCTs of solid tumor or lymphoma patients randomized to CT ± primary G-CSF support, ≥2 years follow-up and reporting AML/MDS or all second malignancies.
  • Primary outcomes were AML/MDS and mortality.
  • 12,642 patients were randomized to CT ± primary G-CSF support.
  • Second malignancies were reported in 3.3% and 3.2% with and without G-CSF, respectively (P=.942).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964513.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Huang J, Cai GR, Zhang JM, Wang WJ, Da Chu T, Sun Y: Phase II study of paclitaxel and cisplatin in advanced esophageal cancer: A Chinese esophageal cancer group. J Clin Oncol; 2004 Jul 15;22(14_suppl):4173

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 4173 Background: Esophageal cancer is not common in western countries, but it is one of the most frequent malignancies and the second leading cause of death from cancer in china.
  • Paclitaxel is one of the most active single agents in the treatment of metastatic esophageal cancer.
  • The antitumor response, toxicity and survival of patients treated with the two-drug regimen were evaluated.
  • 3 patients had previous adjuvant chemotherapy.
  • Treatment was recycled every 21 days.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013846.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Rubio-Martínez A, Recasens V, Martos C, Montañés A, García-Carpintero G, Gómez-López L, Rubio-Félix D, Giraldo P: Predictive factors to develop a second neoplasia in a Hodgkin disease cohort patients. J Clin Oncol; 2004 Jul 15;22(14_suppl):6707

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors to develop a second neoplasia in a Hodgkin disease cohort patients.
  • : 6707 Background: Hodgkin's lymphoma (HL) is a rare malignancy, incidence rate (IR): 2.4/105 inh/y, 85% can be cured.
  • The importance of late effects of therapy have become more apparent.
  • PURPOSE: to determine the IR of second malignancies (SM)in HL and to compare with cancer IR in general population during 1978-1998.
  • VARIABLES: demographic data, date of HL diagnosis, histological subtype, stage, treatment schedule (chemotherapy, radiotherapy, combined), date SM diagnosis, subtype and location of cancer.
  • Cohort was stratified according to age, gender and schedule of therapy.
  • Other risk factors related to cancer were considered (smoke, toxic contacts, previous neoplasia).
  • Radiotherapy 16.1% (mantle 50%, inverted-Y 11.8 %, both: 1.6%;cobalt 59.3%, linear accelerator 4.2%; total dose 20-36 Gy), chemotherapy 39.8% (ABVD 14.4%, MOPP 15.5%, CMOPP 23.7%, CMOPP/ABVD 18.6%, ABVD/MOPP 15.2%), combined 44%.
  • HL relapsed: 10.1%, mean time: 49 m.
  • Developed a SM 15(12.7%), mean 102.3 m; range 9-285: 11 a non-hematological neoplasia: adenocarcinoma (colon, breast, lung, oropharynx, skin, cavum, parotida. thyroid) and 4 a hematological neoplasia (AML and NHL).
  • The global risk of cancer in HL was 10.0 and 6.5 when only non hematological tumor were considered.
  • CONCLUSIONS: The incidence of SM among long-time survivors of HL is higher than in normal population.
  • In other essays the major risk has been observed in patients treated with radiotherapy either alone or combined with chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014611.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Petrakova K, Koukalová H, Soumarová R, Palácov' M, Blažkova S, Vyzula R: Relative risk (RR) of second malignancies (SM) in patients treated by "risk" radiotherapy (RT) or "risk" RT plus chemotherapy (CT) in comparison with patients treated by CT ± "non risk RT" for Hodgkin's disease (HD). J Clin Oncol; 2004 Jul 15;22(14_suppl):6695

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relative risk (RR) of second malignancies (SM) in patients treated by "risk" radiotherapy (RT) or "risk" RT plus chemotherapy (CT) in comparison with patients treated by CT ± "non risk RT" for Hodgkin's disease (HD).
  • : 6695 Background: Late effect, in particular second malignancies, kill more patients with HD then the disease itself.
  • METHODS: 851 patients (475 men and 376 women) with survival time after HD diagnosis >1 year were treated in MOÚ during 1967-1995.
  • 74 cases of SM developed in the cohort.
  • CONCLUSION: The relative risk of solid tumors as second malignancies increased with the time of follow-up.
  • Treatment by "risk RT" increases RR of breast cancer, colorectal cancer, gynecologic cancer and slightly thyroid cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014399.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Vachin F, Hans S, Atlan D, Brasnu D, Menard M, Laccourreye O: [Long term results of exclusive chemotherapy for glottic squamous cell carcinoma complete clinical responders after induction chemotherapy]. Ann Otolaryngol Chir Cervicofac; 2004 Jun;121(3):140-7
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long term results of exclusive chemotherapy for glottic squamous cell carcinoma complete clinical responders after induction chemotherapy].
  • [Transliterated title] Résultats à long-terme de la chimiothérapie exclusive des cancers épidermoïdes glottiques.
  • OBJECTIVES: To evaluate the long-term results of exclusive chemotherapy for T1-T3N0M0 glottic squamous cell carcinoma complete clinical responders after induction chemotherapy.
  • MATERIAL AND METHODS: Between 1985 and 2000, 69 patients with glottic squamous cell carcinoma complete clinical responders after induction chemotherapy were managed with exclusive chemotherapy at our department.
  • Chemotherapy associated platinum and fluorouracil.
  • This retrospective analysis evaluated actuarial survival, treatment morbidity, oncologic events and laryngeal preservation.
  • Chemotherapy never resulted in death.
  • The 10-year actuarial metachronous second primary tumors estimate was 32%.
  • CONCLUSION: Altogether our data and the review of the literature suggest that in patients achieving a complete clinical response after and induction based chemotherapy regimen, the completion of an exclusive chemotherapy regimen appears to be a valid alternative to the conventional use of radiotherapy or chemo-radiation protocols.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Glottis / pathology. Laryngeal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Outcome Assessment (Health Care). Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15223999.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


30. Alebouyeh M, Moussavi F, Haddad-Deylami H, Vossough P: Hodgkin lymphoma as second malignancy during continuing chemotherapy for childhood acute lymphoblastic leukemia. Klin Padiatr; 2008 Nov-Dec;220(6):388-90
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma as second malignancy during continuing chemotherapy for childhood acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia (ALL) is the most prevalent childhood malignancy in most parts of the world with a 5-year survival rate above 70%.
  • Long-term survivors are at risk for treatment-related late effects and second malignant neoplasms (SMNs).
  • SMNs occur with a mean latency of 6-6.7 years after ALL diagnosis but are rarely observed during maintenance chemotherapy (CT).
  • We report two children with ALL who developed HL while receiving maintenance CT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hodgkin Disease / chemically induced. Neoplasms, Second Primary / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Biopsy. Child, Preschool. Follow-Up Studies. Humans. Long-Term Care. Lymph Nodes / pathology. Male. Neoplasm Staging


31. Chiappa A, Bertani E, Makuuchi M, Zbar AP, Contino G, Viale G, Pruneri G, Bellomi M, Della Vigna P, Zampino MG, Fazio N, Travaini ML, Trifirò G, Corbellini C, Andreoni B: Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastases. Hepatogastroenterology; 2009 May-Jun;56(91-92):829-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastases.
  • BACKGROUND/AIMS: Hepatic resection in metastatic disease from colorectal cancer offers the best chance in selected cases for long-term survival.
  • Neoadjuvant chemotherapy (NACT) has been advocated in some cases initially deemed irresectable with few reports of the efficacy of such a strategy and the influence of the response to chemotherapy on the outcome of radical hepatic resection.
  • Twenty-five of these patients, (7 males, 18 females, mean age: 58+/-9 years; range: 40-75 years) deemed as resectable cases at the time of diagnosis were treated with neoadjuvant chemotherapy.
  • Chemotherapy included mainly oxaliplatin or irinotecan containing regimens for a median of 6 courses.
  • RESULTS: Fifteen patients (60%) had synchronous and 10 (40%) metachronous metastases.
  • During preoperative chemotherapy tumor regression occurred in 8 cases (32%); stable disease (SD) in a further 10 patients (40%) and progressive disease (PD) developed in 7 cases (28%).
  • CONCLUSIONS: The response to chemotherapy is likely to be a significant prognostic factor affecting overall survival after radical hepatic resection for colorectal metastases.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Colonic Neoplasms / pathology. Hepatectomy. Liver Neoplasms / mortality. Liver Neoplasms / therapy. Rectal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cohort Studies. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19621711.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


32. Sasaki S, Ishimaru M, Suzuki H, Ogawa M, Sato Y: [Significance of CEA to predict the effect of chemotherapy with bevacizumab]. Gan To Kagaku Ryoho; 2010 Mar;37(3):463-7
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Significance of CEA to predict the effect of chemotherapy with bevacizumab].
  • PURPOSE: Since chemotherapy with bevacizumab has become available for advanced colorectal cancer, its effectiveness has been reported.
  • The purpose of this study was to evaluate the significance of CEA to predict the effect of chemotherapy with bevacizumab.
  • SUBJECTS AND METHODS: Twenty-five patients with advanced colorectal cancer were given chemotherapy with bevacizumab since August 2007.
  • Chemotherapy with bevacizumab was given for 7 cases with metachronous recurrences after curative operations (6 cases with liver and/or lung metastasis and 1 case with pelvic recurrence), and for 11 cases with synchronous liver and/or lung metastasis.
  • First-line chemotherapy was given to 16 cases and second-line to 2 cases.
  • The response rate in 3 cases whose CEA was within the normal range before chemotherapy was 100%.
  • CONCLUSION: In chemotherapy with bevacizumab, the response rate in patients with normal CEA was higher than that in patients with high CEA.
  • Patients with a CEA level of 100 ng/mL or more had a short CEA-controlled period, suggesting the effect of chemotherapy was small in those patients.
  • There is a possibility that CEA might be clinically useful as a biomarker to predict treatment efficacy in chemotherapy with bevacizumab.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Biomarkers / analysis. Carcinoembryonic Antigen / analysis. Colorectal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bevacizumab. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20332684.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers; 0 / Carcinoembryonic Antigen; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


33. Longhi A, Pasini E, Bertoni F, Pignotti E, Ferrari C, Bacci G: Twenty-year follow-up of osteosarcoma of the extremity treated with adjuvant chemotherapy. J Chemother; 2004 Dec;16(6):582-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Twenty-year follow-up of osteosarcoma of the extremity treated with adjuvant chemotherapy.
  • We have updated the results of an adjuvant chemotherapy study of 106 patients with osteosarcoma of the extremities published 17 years ago, treated by surgery followed by adjuvant chemotherapy with vincristine (VCR), methotrexate (MTX) and doxorubicin (ADM), between 1980-1983, and followed-up for at least 20 years (20-23 years).
  • In comparison with the results reported 17 years ago with a median follow-up of 38 months (range: 27-66), this updated study showed 24 more deaths, 9 more relapses and 3 second malignancies.
  • We conclude that osteosarcoma patients treated with chemotherapy are at risk of late adverse events.
  • Protracted medical follow-up and long-term updated results are useful to identify, at an early stage, late relapses and late treatment-related complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Morbidity. Risk Factors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Osteosarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15700851.001).
  • [ISSN] 1120-009X
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] Italy
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


34. Bonfils P, Trotoux J, Bassot V: Chemotherapy alone in laryngeal squamous cell carcinoma. J Laryngol Otol; 2007 Feb;121(2):143-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy alone in laryngeal squamous cell carcinoma.
  • AIMS: To evaluate the results of chemotherapy alone in patients with invasive squamous cell carcinoma of the larynx who have achieved a complete clinical response after an induction chemotherapy protocol.
  • METHODS: A comparison of results in a group of complete responders managed with a chemotherapy alone protocol, matched with those of an incomplete responder group managed with conventional modalities.
  • CONCLUSION: Our results confirm the fact that chemotherapy alone is a viable option in selected patients with carcinoma of the larynx who have achieved a complete clinical response after an induction chemotherapy protocol.
  • This therapeutic approach allows surgery and/or radiation therapy to be reserved for the management of metachronous second primary tumours.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Laryngeal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17005065.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


35. Takeno A, Fujitani K, Tsujinaka T, Hirao M, Takeda Y, Kashiwazaki M, Mishima H, Ikenaga M, Sawamura T, Hasuike Y: [Evaluation of arterial infusion chemotherapy for liver metastasis from gastric cancer]. Gan To Kagaku Ryoho; 2003 Oct;30(11):1631-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of arterial infusion chemotherapy for liver metastasis from gastric cancer].
  • We evaluated the effectiveness of arterial infusion chemotherapy for liver metastasis from gastric cancer.
  • Nineteen patients (9 synchronous cases, 10 metachronous cases) were treated with hepatic arterial infusion chemotherapy (HAIC).
  • The response rate was 26% (CR 3, PR 2, PD 14), and the median survival time was 357 days after the diagnosis of liver metastasis.
  • The treatment was discontinued in 8 patients because of treatment associated complications and disease progression.
  • The combination of systemic chemotherapy with HAIC tended to improve the prognosis.
  • It may be necessary to reevaluate HAIC as a treatment modality for liver metastasis from gastric cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Hepatic Artery. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasms, Multiple Primary. Neoplasms, Second Primary. Survival Rate

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14619481.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


36. Balwierz W, Klekawka T, Moryl-Bujakowska A, Matysiak M, Sopyło B, Wachowiak J, Kaczmarek-Kanold M, Sońta-Jakimczyk D, Janik-Moszant A, Chybicka A, Chaber R, Kowalczyk JR, Mitura-Lesiuk M, Balcerska A, Stachowicz-Stencel T, Wysocki M, Kołtan A, Krawczuk-Rybak M, Muszyńska-Rosłan K, Młynarski W, Stolarska M, Sobol G, Wieczorek M, Karolczyk G, Urbanek-Dadela A: [Can children with Hodgkin's disease be treated with chemotherapy only?]. Przegl Lek; 2010;67(6):375-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Can children with Hodgkin's disease be treated with chemotherapy only?].
  • [Transliterated title] Czy dzieci z choroba Hodgkina moga być leczone wyłacznie chemioterapia?
  • Currently over 90% of children and adolescents with Hodgkin's disease (HD) can be cured thanks to use of multidrug chemotherapy (CT) combined with involved-field radiotherapy (IF-RT).
  • However, the intensive treatment may increase the risk of late complications which may impair the patients' quality of life.
  • This study presents the treatment results of patients treated with CT only in comparison with the therapy results of children treated with CT and IF-RT.
  • In 45 patients with IA-IIA stages presenting favorable risk factors (small mediastinal tumor, peripheral nodular mass of a maximum diameter < 6 cm, involvement of less than three nodular regions, ESR < 50 mm after 1 h, histologic type other than lymphocyte depletion and very good treatment response assessed after 3 CT cycles) IF-RT was omitted.
  • All serious late complications (including 7 second neoplasms) occurred in patients treated with CT combined with RT.
  • Our results show that the use of CT only in precisely selected group of patients with HD do not impair the treatment results and may decrease the risk of late life threatening complications.
  • Treatment response assessment with the use of PET may in future increase the number of patients treated without RT and limit the need of the use of invasive diagnostic methods in patients with residual mass.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Male. Neoplasm Staging. Radiotherapy, Adjuvant. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21344765.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


37. Ceelen W, Van Nieuwenhove Y, Pattyn P: Surgery and intracavitary chemotherapy for peritoneal carcinomatosis from colorectal origin. Acta Gastroenterol Belg; 2008 Oct-Dec;71(4):373-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery and intracavitary chemotherapy for peritoneal carcinomatosis from colorectal origin.
  • A subset of patients with colorectal cancer (CRC) develops synchronous or metachronous isolated peritoneal disease.
  • The development of peritoneal carcinomatosis (PC) can be conceptualized as a series of well defined steps including cell shedding, adhesion to mesothelial cells and underlying matrix, and invasion of submesothelial tissue.
  • In this review, we discuss the biological rationale, clinical methods, and oncological outcomes associated with cytoreduction and intracavitary chemotherapy in CRC patients suffering from peritoneal disease spread.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma / drug therapy. Carcinoma / surgery. Colorectal Neoplasms / pathology. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Humans. Infusions, Parenteral

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317277.001).
  • [ISSN] 1784-3227
  • [Journal-full-title] Acta gastro-enterologica Belgica
  • [ISO-abbreviation] Acta Gastroenterol. Belg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 52
  •  go-up   go-down


38. Wenzel C, Urbauer E, Schwarz C, Funk G, Oehler L, Kornek GV, Scheithauer W: Severe enteropathy associated with raltitrexed and oxaliplatin chemotherapy: report of two patients experiencing this rare, potentially lethal gastrointestinal adverse event. Anticancer Drugs; 2006 Aug;17(7):865-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe enteropathy associated with raltitrexed and oxaliplatin chemotherapy: report of two patients experiencing this rare, potentially lethal gastrointestinal adverse event.
  • Among the several different combination chemotherapy regimens for the treatment of patients with metastatic colorectal cancer, oxaliplatin plus raltitrexed has shown encouraging therapeutic results and a fairly good toxicity profile.
  • Here, we report on two patients with metastatic colorectal cancer receiving this combination therapy, which leads to severe enterocolitis and neutropenia resulting in death in one patient.
  • The other patient was a 74-year-old woman with colon cancer, and metachronous multiple pulmonal and hepatic metastases.
  • In both patients, palliative chemotherapy consisted of oxaliplatin 130 mg/m2 in combination with raltitrexed 3 mg/m2 on day 1 every 21 days.
  • Both patients developed neutropenia in combination with severe enterocolitis after the fourth and the second chemotherapy cycle, respectively.
  • Despite antibiotic treatment, diarrhea persisted in both patients for weeks.
  • Severe enterocolitis, a hitherto infrequently recognized adverse event, which has been described in association with 5-fluorouracil/leucovorin and oxaliplatin chemotherapy, may also occur with raltitrexed and oxaliplatin.
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / drug therapy. Aged. Breast Neoplasms / pathology. Colonoscopy. Colorectal Neoplasms / complications. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / pathology. Diabetes Complications. Diabetes Mellitus, Type 1. Drug Therapy, Combination. Enterocolitis / chemically induced. Enterocolitis / pathology. Fatal Outcome. Female. Humans. Lung Neoplasms / complications. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16926637.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Organoplatinum Compounds; 0 / Quinazolines; 0 / Thiophenes; 04ZR38536J / oxaliplatin; FCB9EGG971 / raltitrexed
  •  go-up   go-down


39. Tourani JM, Jaillon-Abraham C, Coscas Y, Dabouis G, Andrieu JM: Feasibility and preliminary results of intensive chemotherapy and extensive irradiation in selected patients with limited small-cell lung carcinoma--results of three consecutive phase II programs. Acta Oncol; 2000;39(4):501-8
Hazardous Substances Data Bank. VINDESINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility and preliminary results of intensive chemotherapy and extensive irradiation in selected patients with limited small-cell lung carcinoma--results of three consecutive phase II programs.
  • We report the results of three consecutive programs combining initial intensive chemotherapy and radiotherapy in the treatment of patients with limited small-cell lung cancer (SCLC).
  • The objective was to test the feasibility and the effect of high-dose chemotherapy and three thoracic irradiation programs on survival and patterns of relapse.
  • All patients received high-dose chemotherapy (vindesine, etoposide, doxorubicin, cisplatin and cyclophosphamide or ifosfamide).
  • In the SC 84 program, chest and brain radiotherapy was delivered during each course of chemotherapy, with a complementary irradiation after chemotherapy.
  • In the SC 86 and SC 92 programs, patients received chemotherapy followed by thoracic irradiation and prophylactic brain and spinal axis radiotherapy.
  • At the end of treatment, 40 patients (95%) were in complete response.
  • During chemotherapy, high levels of toxicity were noted.
  • Five patients developed late toxicities and a second malignancy was observed in 4 patients.
  • Despite the marked toxicity of the initial intensive chemotherapy, the treatments are tolerable and effective in the control of extra-thoracic micrometastases, whereas they are less effective for thoracic primary tumor.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Feasibility Studies. Female. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Radiotherapy Dosage. Survival Analysis. Treatment Outcome. Vindesine / administration & dosage

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11041113.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] NORWAY
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; RSA8KO39WH / Vindesine; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


40. Aleman BM, Raemaekers JM, Tomiŝiĉ R, Baaijens MH, Bortolus R, Lybeert ML, van der Maazen RW, Girinsky T, Demeestere G, Lugtenburg P, Lievens Y, de Jong D, Pinna A, Henry-Amar M, European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group: Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys; 2007 Jan 1;67(1):19-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.
  • The purpose of this study was to describe the role of radiotherapy in patients with advanced HL who were in partial remission (PR) after chemotherapy.
  • METHODS: In a prospective randomized trial, patients <70 years old with previously untreated Stage III-IV HL were treated with six to eight cycles of mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycine, vinblastine hybrid chemotherapy.
  • Patients in complete remission (CR) after chemotherapy were randomized between no further treatment and involved-field radiotherapy (IF-RT).
  • Those in PR after six cycles received IF-RT (30 Gy to originally involved nodal areas and 18-24 Gy to extranodal sites with or without a boost).
  • RESULTS: Of 739 enrolled patients, 57% were in CR and 33% in PR after chemotherapy.
  • Patients in PR had bulky mediastinal involvement significantly more often than did those in CR after chemotherapy.
  • The incidence of second malignancies in patients in PR who were treated with IF-RT was similar to that in nonirradiated patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Logistic Models. Male. Mechlorethamine / administration & dosage. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / mortality. Mediastinal Neoplasms / radiotherapy. Middle Aged. Neoplasms, Second Primary / etiology. Prednisone / administration & dosage. Procarbazine / administration & dosage. Remission Induction. Survival Rate. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17097834.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone
  •  go-up   go-down


41. Strumberg D, Brügge S, Korn MW, Koeppen S, Ranft J, Scheiber G, Reiners C, Möckel C, Seeber S, Scheulen ME: Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol; 2002 Feb;13(2):229-36
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer.
  • PATIENTS AND METHODS: Thirty-two patients treated with cisplatin- and doxorubicin-containing chemotherapy > or = 13 years before the time of analyses were evaluated for neuro-, oto-, pulmonary-, vascular- and gonadal toxicity including evaluation of myocardial damage and cardiovascular risk factors and analysis of microcirculation.
  • About 25% of the patients developed diastolic arterial hypertension after chemotherapy.
  • CONCLUSIONS: Patients cured by cisplatin-based chemotherapy for metastatic testicular cancer have to be cognizant of their unfavorable cardiovascular risk profile, that might be a greater risk than developing a relapse or second malignancy.

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2002 Feb;13(2):187-9 [11885993.001]
  • (PMID = 11885999.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


42. Benazzo M, Caracciolo G, Zappoli F, Bernardo G, Mira E: Induction chemotherapy by superselective intra-arterial high-dose carboplatin infusion for head and neck cancer. Eur Arch Otorhinolaryngol; 2000;257(5):279-82
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemotherapy by superselective intra-arterial high-dose carboplatin infusion for head and neck cancer.
  • To evaluate the feasibility, maximum dose of drug tolerated, technical problems, systemic and local toxicity, response rate, overall and disease-free survival, we studied superselective intra-arterial infusion of high-dose carboplatin as part of a multimodality treatment for head and neck cancer.
  • Forty patients with untreated stage II-IV head and neck squamous cell carcinomas received induction chemotherapy with high-dose carboplatin (three cycles at 2-week intervals using 300-350 mg/m2 per cycle), delivered via superselective transfemoral angiography followed by radiotherapy or surgery plus radiotherapy.
  • At the end of chemotherapy the overall complete and partial response rate was 90% (36/40) at the primary site and 64% (16/25) at the neck nodes.
  • To date 21 patients are alive without disease, 2 are alive with disease, 13 have died of disease, and 4 have developed a metachronous lung tumor.
  • There was a good correlation between the response to chemotherapy and disease-free survival.
  • However, discriminating between responding and nonresponding patients, this procedure can have a prognostic significance in planning integrated treatments for these types of tumors.
  • [MeSH-major] Carboplatin / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Infusions, Intra-Arterial. Otorhinolaryngologic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infusion Pumps. Male. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10923944.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin
  •  go-up   go-down


43. Bacci G, Ferrari C, Longhi A, Ferrari S, Forni C, Bacchini P, Palmerini E, Briccoli A, Pignotti E, Balladelli A, Picci P: Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy. J Pediatr Hematol Oncol; 2006 Dec;28(12):774-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy.
  • We evaluated the rate of second malignancies in 1205 patients with osteosarcoma of the extremity treated at our Institution with different protocols of adjuvant and neoadjuvant chemotherapy.
  • Twenty-six patients (2.15%) developed a second malignant neoplasm at a median of 7.6 years (1 to 25 y) after primary osteosarcoma treatment.
  • Of these, 2 developed a third cancer which were not considered in the series.
  • Second neoplasms were leukemia (10), breast (7), lung (2), kidney (2), central nervous system cancer (2), soft tissue (1), parotid (1), and colon (1).
  • The rate of second neoplasms was significantly higher in female patients, and the latent period shorter in hematologic tumors compared with solid tumors.
  • Ten of these 26 patients are disease free at a median of 7.7 years (range 1 to 15 y) after the last treatment.
  • The rate of second malignancies observed in the osteosarcoma group was significantly higher than that observed in the control group of 1160 patients with benign tumors treated in the same period at our Institute (2.2% vs. 0.8%, P<0.009).
  • Our study showed that the risk of second neoplasm within 15 years increased and then leveled off and that although secondary solid tumors could be explained as unrelated cases, leukemias seem to be over represented.
  • [MeSH-major] Neoplasms, Second Primary / epidemiology. Osteosarcoma
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant / methods. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Incidence. Infant. Male. Neoplasms / drug therapy. Neoplasms / epidemiology. Retrospective Studies. Risk Factors. Sex Factors. Time Factors

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164644.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


44. Culliford AT 4th, Brooks AD, Sharma S, Saltz LB, Schwartz GK, O'Reilly EM, Ilson DH, Kemeny NE, Kelsen DP, Guillem JG, Wong WD, Cohen AM, Paty PB: Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. Ann Surg Oncol; 2001 Dec;8(10):787-95
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer.
  • BACKGROUND: Aggressive treatment of peritoneal metastases from colon cancer by surgical cytoreduction and infusional intraperitoneal (IP) chemotherapy may benefit selected patients.
  • Primary tumor sites were 47 in the colon and 17 in the appendix.
  • Peritoneal metastases were synchronous in 48 patients and metachronous in 16 patients.
  • The median number of complications was 1 (range, 0-5), with no treatment related mortality.
  • Only six patients (9%) required termination of IP chemotherapy because of complications.
  • Lymph node status, tumor grade, and interval to peritoneal metastasis were not statistically significant prognostic factors for survival.
  • Complete tumor resection was significant on multivariate analysis (P = .04), with a 5-year survival of 54% for complete (n = 19) and 16% for incomplete (n = 45) resection.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Appendiceal Neoplasms. Colonic Neoplasms. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Antimetabolites, Antineoplastic / therapeutic use. Combined Modality Therapy. Female. Floxuridine / therapeutic use. Formyltetrahydrofolates / therapeutic use. Humans. Infusions, Parenteral / methods. Leucovorin / therapeutic use. Male. Middle Aged. Retrospective Studies. Survival Analysis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2001 Dec;8(10):754-5 [11776486.001]
  • (PMID = 11776492.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Formyltetrahydrofolates; 039LU44I5M / Floxuridine; Q573I9DVLP / Leucovorin
  •  go-up   go-down


45. Ibrahim NK, Buzdar AU, Asmar L, Theriault RL, Hortobagyi GN: Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up. Ann Oncol; 2000 Dec;11(12):1597-601
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up.
  • BACKGROUND: The purpose of this study was to evaluate the clinical outcome of doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients and to compare results in elderly patients with those in younger patients.
  • PATIENTS AND METHODS: We retrospectively reviewed the records of all patients aged 50 years or older treated in trials of doxorubicin-based adjuvant chemotherapy between 1974 and 1988.
  • RESULTS: A total of 390 patients aged 50 years or older were treated with doxorubicin-based adjuvant chemotherapy during the study period.
  • There were no statistically significant differences between the two groups with respect to performance status, hormone receptor profile, tumor size, nodal status, or type of locoregional therapy.
  • There also were no statistically significant differences between the two groups in recurrence patterns, disease-free survival, or overall survival.
  • The occurrence of second malignancies was extremely low in both groups.
  • In both groups, the majority of deaths were due to progression of disease.
  • CONCLUSIONS: Adjuvant doxorubicin-based chemotherapy is well tolerated in elderly breast cancer patients who have good performance status and normal cardiac ejection fraction.
  • Adjuvant doxorubicin-based chemotherapy in these patients results in disease-free and overall survival rates similar to those seen in younger patients.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2001 Aug;12(8):1180-1 [11583205.001]
  • (PMID = 11205469.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin
  •  go-up   go-down


46. Labianca R, Fossati R, Zaniboni A, Torri V, Marsoni S, Nitti D, Boffi L, Scatizzi M, Tardio B, Mastrodonato N, Banducci S, Consani G, Pancera G, ACOI/GIVIO/GISCAD Investigators: Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma. J Natl Cancer Inst; 2004 May 19;96(10):750-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma.
  • BACKGROUND: 5-fluorouracil-based adjuvant chemotherapy after surgical resection of colon cancer is standard treatment.
  • In a randomized clinical trial of patients with colon cancer, we compared the benefits of chemotherapy delivered by these routes individually or in combination.
  • METHODS: From April 2, 1992, through April 30, 1998, 1084 eligible patients with Dukes' stage B or C colon carcinoma were randomly assigned: 369 patients to the IP regimen (continuous portal vein infusion of 5-fluorouracil at 500 mg/m2 of body surface daily and heparin at 5000 IU daily for 7 consecutive days, beginning on the day of surgery), 358 patients to the SY regimen (six 28-day courses of systemic leucovorin at 100 mg/m2 daily on days 1 through 5 followed by systemic bolus 5-fluorouracil at 370 mg/m2 daily on days 1 through 5, with treatment initiated 15-35 days after surgery), and 357 patients to the IP+SY regimen (the IP regimen followed by the SY regimen, with the same scheduling).
  • Primary survival was analyzed with the log-rank statistic and a Cox multivariable regression model.
  • RESULTS: At a median follow-up time of 99 months, 389 events (recurrences, second malignancies, or deaths) had occurred, and 361 patients died.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colonic Neoplasms / drug therapy. Portal Vein
  • [MeSH-minor] Administration, Oral. Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Italy. Leucovorin / administration & dosage. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Research Design. Risk Factors. Survival Analysis. Treatment Outcome

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2004 May 19;96(10):727-9 [15150295.001]
  • (PMID = 15150303.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


47. Grundy RG, Wilne SA, Weston CL, Robinson K, Lashford LS, Ironside J, Cox T, Chong WK, Campbell RH, Bailey CC, Gattamaneni R, Picton S, Thorpe N, Mallucci C, English MW, Punt JA, Walker DA, Ellison DW, Machin D, Children's Cancer and Leukaemia Group (formerly UKCCSG) Brain Tumour Committee: Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol; 2007 Aug;8(8):696-705
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study.
  • As an adjuvant treatment, radiotherapy can be effective, but has the potential to damage the child's developing nervous system at a crucial time-with a resultant reduction in IQ and cognitive impairment, endocrinopathy, and risk of second malignancy.
  • We aimed to assess the role of a primary chemotherapy strategy in avoiding or delaying radiotherapy in children younger than 3 years with intracranial ependymoma.
  • METHODS: Between December, 1992, and April, 2003, we enrolled 89 children with ependymoma who were aged 3 years or younger at diagnosis, of whom nine had metastatic disease on pre-operative imaging.
  • After maximal surgical resection, children received alternating blocks of myelosuppressive and non-myelosuppressive chemotherapy every 14 days for an intended duration of 1 year.
  • Radiotherapy was withheld unless local imaging (ie, from the child's treatment centre) showed progressive disease.
  • FINDINGS: 50 of the 80 patients with non-metastatic disease progressed, 34 of whom were irradiated for progression.
  • There was no significant difference in event-free or overall survival between complete and incomplete surgical resection, nor did survival differ according to histological grade, age at diagnosis, or site of disease.
  • The median time to progression for the 59 patients who progressed was 1.6 years (range 0.1-10.2 years).
  • For the 80 non-metastatic patients, the 23 who achieved the highest relative dose intensity of chemotherapy had the highest post-chemotherapy 5-year overall survival of 76% (95% CI 46.6-91.2), compared with 52% (33.3-68.1) for the 32 patients who achieved the lowest relative dose intensity of chemotherapy.
  • These results suggest, therefore, that primary chemotherapy strategies have an important role in the treatment of very young children with intracranial ependymoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Ependymoma / drug therapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Child. Child, Preschool. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Female. Humans. Infant. Male. Methotrexate / administration & dosage. Prognosis. Prospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2007 Aug;8(8):665-6 [17679076.001]
  • [CommentIn] Curr Neurol Neurosci Rep. 2009 Mar;9(2):94-6 [19268030.001]
  • [CommentIn] Lancet Oncol. 2007 Sep;8(9):758-9; author reply 760-1 [17765188.001]
  • (PMID = 17644039.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


48. Woodward WA, Strom EA, McNeese MD, Perkins GH, Outlaw EL, Hortobagyi GN, Buzdar AU, Buchholz TA: Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy. Int J Radiat Oncol Biol Phys; 2003 Oct 1;57(2):327-35
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy.
  • PURPOSE: To assess the incidence of long-term toxicity after postmastectomy radiation and doxorubicin-based adjuvant chemotherapy.
  • METHODS: Records of 470 patients treated with mastectomy, doxorubicin-based chemotherapy, and postmastectomy radiation in five institutional prospective trials were retrospectively reviewed.
  • Actuarial toxicity rates were compared with those of 1031 patients treated with mastectomy and doxorubicin-based chemotherapy who did not receive postmastectomy radiation.
  • For those treated with radiation, the chest wall received a median dose of 55 Gy with Co-60 (42%) or electrons (51%).
  • Adjuvant chemotherapy consisted of a doxorubicin-based regimen, often followed by 2 years of cyclophosphamide, methotrexate, and fluorouracil.
  • The overall 10- and 15-year actuarial rates of second non-breast cancer malignancy were 3.8% and 7%, respectively.
  • There was no statistical difference between the rates of non-breast cancer second malignancy in the radiated and unirradiated cohorts (3.4% vs. 4.7% 10-year actuarial rates).
  • Increasing age and treatment with >10 cycles of chemotherapy were associated with higher rates of second malignancy (p = 0.025, p = 0.016).
  • CONCLUSIONS: We found very low rates of serious sequelae after postmastectomy radiation, including death from myocardial infarction and non-breast cancer second malignancy.
  • The rate of second non-breast cancer malignancy was increased among patients treated with >10 cycles of cyclophosphamide-containing chemotherapy.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy. Myocardial Infarction / mortality. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adult. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Doxorubicin / therapeutic use. Female. Humans. Middle Aged. Radiotherapy / adverse effects. Radiotherapy Dosage. Retrospective Studies. Tamoxifen / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Heart Attack.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):319-20; author reply 320 [15093931.001]
  • (PMID = 12957242.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / T32CA77050
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen; 80168379AG / Doxorubicin
  •  go-up   go-down


49. Honda I, Kobayashi D, Fukumoto R, Matsushita H, Hattori M, Nagata M, Watanabe S: [Second malignancy after gastrectomy for early gastric cancer-is there any evidence that adjuvant chemotherapy for early gastric cancer causes a second malignancy ?]. Gan To Kagaku Ryoho; 2008 Aug;35(8):1341-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Second malignancy after gastrectomy for early gastric cancer-is there any evidence that adjuvant chemotherapy for early gastric cancer causes a second malignancy ?].
  • The common causes of post-operative death in early gastric cancer are other diseases and second malignancy.
  • In Japan, adjuvant chemotherapy using oral administration of 5-fluorouracil is widely accepted in spite of no statistical evidence until the presentation by Kinoshita in 2005.
  • In 1999, Fujimoto mentioned that adjuvant chemotherapy and chemo-immune-therapy cause a second malignancy.
  • Adjuvant chemotherapy was once the standard treatment for early gastric cancer patients.
  • So, we investigated the relation between adjuvant chemotherapy and second malignancy for early gastric cancer patients.
  • As a result, adjuvant chemotherapy using 5-fluorouracil(Tegafur)did was not cause second malignancy under multivariate analysis.
  • The most important factor in second malignancy with post-operative early gastric cancer patients was heredity(cancer within first-degree relatives).
  • From this point of view, early gastric patients after gastrectomy and endoscopic treatment are necessary in regular examinations to detect other organ cancers and remnant gastric cancer, especially in patients with hereditary factors.
  • [MeSH-major] Chemotherapy, Adjuvant. Gastrectomy. Neoplasms, Second Primary / epidemiology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / epidemiology
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Neoplasm Staging. Risk Factors. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701845.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


50. Yoda Y, Yoshino T, Kadowaki S, Bando H, Okano S, Fukushima H, Fuse N, Tahara M, Doi T, Ohtsu A: [Two cases of KRAS wild-type unresectable or recurrent colorectal cancer effectively treated by cetuximab after progression of prior chemotherapy]. Gan To Kagaku Ryoho; 2009 Jun;36(6):1003-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of KRAS wild-type unresectable or recurrent colorectal cancer effectively treated by cetuximab after progression of prior chemotherapy].
  • We reported two cases of unresectable or recurrent colorectal cancer effectively treated by cetuximab after the progression of the prior chemotherapy.
  • He received cetuximab plus irinotecan combination therapy in the third-line setting.
  • Amonth after the initiation of the chemotherapy, abdominal CT showed tumor shrinkage of liver metastases.
  • Case 2: A57-year-old female suffered from sigmoid colon cancer with metachronous liver, ovarian metastases, ascites and pleural effusion.
  • Five weeks after initiation of chemotherapy, her chest, abdominal and pelvic CT showed tumor shrinkage of the liver metastases and the reduction of both ascites and pleural effusion, together with resolution of her dyspnea on exertion.
  • Before cetuximab administration, we investigated KRAS status on cancer tissue previously resected in the above 2 cases, which showed KRAS wild-type.
  • Cetuximab could be effective for KRAS wild-type colorectal cancer, as well as the previous reports from Western countries.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Colorectal Neoplasms / drug therapy. Proto-Oncogene Proteins / genetics. ras Proteins / genetics
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cetuximab. Female. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542725.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 7673326042 / irinotecan; EC 3.6.5.2 / ras Proteins; PQX0D8J21J / Cetuximab; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


51. Franklin M, Trevino J, Hernandez-Oaknin H, Fisher T, Berghoff K: Laparoscopic hepatic artery catheterization for regional chemotherapy: is this the best current option for liver metastatic disease? Surg Endosc; 2006 Apr;20(4):554-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic hepatic artery catheterization for regional chemotherapy: is this the best current option for liver metastatic disease?
  • BACKGROUND: Metastatic disease isolated to the liver is present at the time of diagnosis in 20-30% of patients with colorectal cancer.
  • Systemic chemotherapy remains the primary treatment modality for such patients.
  • The morbidity associated with regional chemotherapy is largely a result of the laparotomy required to place a hepatic arterial infusion pump in these debilitated patients.
  • We discuss the main advantages of laparoscopic approach in comparison to both open procedure and percutaneous hepatic artery catheterization.
  • 24 patients (88.8%) had bilobar disease precluding surgical resection of the liver metastases.
  • Postoperatively, 16 patients (59.2%) had hepatic intra-arterial chemotherapy in the recovery room as a preplanned protocol.
  • 22 patients with residual hepatic disease, in whom chemotherapy was successfully instituted, showed regression of their metastases, in 18 patients, CEA had improved at their one-month follow-up visit.
  • CONCLUSIONS: In experienced hands, laparoscopic hepatic artery catheterization is a safe, feasible and minimally invasive technique for those patients with metachronous liver malignancies.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Catheterization / methods. Catheters, Indwelling. Colorectal Neoplasms / pathology. Hepatic Artery. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary

  • Genetic Alliance. consumer health - Liver Disease.
  • Genetic Alliance. consumer health - Best Vitelliform Macular Dystrophy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 1996 Apr;10(4):449-52 [8661802.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):301-8 [9440757.001]
  • [Cites] Eur J Surg Oncol. 2002 Dec;28(8):875-90 [12477481.001]
  • [Cites] Surg Gynecol Obstet. 1970 Apr;130(4):581-605 [5436597.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2002 Dec;12(6):398-407 [12496545.001]
  • [Cites] Surg Endosc. 2003 Jan;17(1):61-7 [12360376.001]
  • [Cites] J Clin Invest. 1990 Jun;85(6):1896-904 [2347917.001]
  • [Cites] AJR Am J Roentgenol. 1977 Nov;129(5):799-803 [143878.001]
  • [Cites] Ann Surg. 2004 Jan;239(1):53-60 [14685100.001]
  • [Cites] Hepatogastroenterology. 2002 Mar-Apr;49(44):513-7 [11995485.001]
  • [Cites] Am J Clin Oncol. 2001 Aug;24(4):354-9 [11474260.001]
  • [Cites] Br J Surg. 1993 Aug;80(8):1032-5 [8402060.001]
  • [Cites] Cancer. 1981 Jan 15;47(2):402-9 [6257376.001]
  • [Cites] J Pathol. 1986 Nov;150(3):195-203 [3806280.001]
  • [Cites] Semin Laparosc Surg. 2000 Jun;7(2):140-7 [11320484.001]
  • [Cites] Am J Pathol. 1954 Sep-Oct;30(5):969-77 [13197542.001]
  • [Cites] CA Cancer J Clin. 1991 Jan-Feb;41(1):19-36 [1984806.001]
  • [Cites] Cancer. 1994 Feb 15;73(4):1134-42 [8313315.001]
  • [Cites] J Clin Oncol. 1992 Jul;10(7):1112-8 [1296590.001]
  • [Cites] Cancer Treat Rep. 1980 Jan;64(1):31-40 [6155210.001]
  • [Cites] Arch Surg. 2001 Jun;136(6):700-4 [11387013.001]
  • (PMID = 16508811.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


52. Franklin JG, Paus MD, Pluetschow A, Specht L: Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk. Cochrane Database Syst Rev; 2005;(4):CD003187
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk.
  • BACKGROUND: Second malignancies (SM) are a major late effect of treatment for Hodgkin's disease (HD).
  • Reliable comparisons of SM risk between alternative treatment strategies are lacking.
  • OBJECTIVES: Radiotherapy (RT), chemotherapy (CT) and combined chemo-radiotherapy (CRT) for newly-diagnosed Hodgkin's disease are compared with respect to SM risk, overall (OS) and progression-free (PFS) survival.
  • SELECTION CRITERIA: RCTs accruing 30+ patients and completing accrual before/during 2000, comparing at least two treatment modalities for newly-diagnosed HD.
  • Excess SM with RT is due mainly to ST and is apparently caused by greater need for salvage therapy after RT.CRT was superior to CT in terms of PFS (OR=77, CI 0.68 to 0.77, p<0.0001).
  • This effect, also seen in AL and ST separately, was due directly to first-line treatment.
  • RT alone gives a higher overall SM risk than CRT due to increased need for salvage therapy.
  • Due to the large number of studies excluded because no IPD were received, to the inclusion of many outdated treatments and to the limited amount of long-term data, one must be cautious in applying these results to current therapies.
  • [MeSH-major] Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Combined Modality Therapy. Humans. Randomized Controlled Trials as Topic. Risk Assessment

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16235316.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 127
  •  go-up   go-down


53. Otsuka S, Inagaki M, Miyoshi K, Takahashi M, Oosaki T, Fuchimoto S, Sakata T: [Radiofrequency ablation therapy combined with intrahepatic arterial infusion chemotherapy for liver metastasis of colorectal cancer]. Gan To Kagaku Ryoho; 2003 Oct;30(11):1598-601
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiofrequency ablation therapy combined with intrahepatic arterial infusion chemotherapy for liver metastasis of colorectal cancer].
  • We performed radiofrequency ablation (RFA) therapy combined with intrahepatic arterial infusion chemotherapy for 7 patients with liver metastasis from colorectal cancer.
  • Synchronous metastasis accounted for 5 cases and metachronous for 2 cases.
  • Following the resection of colorectal primary lesion, we performed RFA for liver metastasis, using a Cool-tip electrode purchased from Radionics (Burlington, MA, USA).
  • Ablation time of each session was changed according to tumor size, as follows: less than 1 cm in diameter: 2 min, 2 cm: 5 min, 2.5 cm: 10 min.
  • By using intra-operative catheterization, weekly intrahepatic arterial infusion chemotherapy was performed for liver metastasis.
  • RFA therapy combined with intrahepatic arterial infusion chemotherapy achieved excellent therapeutic effect, and maintained good quality of life in patients.
  • [MeSH-major] Catheter Ablation. Colorectal Neoplasms / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Fluorouracil / administration & dosage. Hepatic Artery. Humans. Infusions, Intra-Arterial. Male. Middle Aged


54. Bilchik AJ, Wood TF, Chawla SP, Rose DM, Chung MH, Stern SS, Foshag LJ, Ramming KP: Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil. Clin Colorectal Cancer; 2001 May;1(1):36-42
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil.
  • Most colorectal cancers metastatic to the liver are resistant to chemotherapy and are not amenable to surgical resection.
  • The patients then received either hepatic arterial floxuridine (FUDR), systemic CPT-11, or no postoperative adjuvant chemotherapy.
  • Number, size, and location of hepatic metastases, carcinoembryonic antigen (CEA) levels, and type of postoperative treatment were analyzed.
  • One to 15 lesions were frozen (median number, 3; median size, 6 cm), for a total of 73 synchronous and 80 metachronous lesions.
  • Overall median survival was 28.4 months from the date of diagnosis of liver metastases and 16.1 months from the time of CSA.
  • Predictors of survival included preoperative CEA, postoperative reduction in CEA, and adjuvant chemotherapy (P < 0.05).
  • Neither size, number of lesions, nor tumor location impacted survival.
  • The 25 patients who underwent a second CSA had a median survival of 28.4 months from CSA and 40 months from the date of diagnosis of liver metastases.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Floxuridine / administration & dosage. Liver Neoplasms / drug therapy. Prodrugs / administration & dosage. Topoisomerase I Inhibitors
  • [MeSH-minor] Chemotherapy, Adjuvant. Chemotherapy, Cancer, Regional Perfusion. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / pathology. Cryosurgery. Disease-Free Survival. Fluorouracil / therapeutic use. Humans. Infusions, Intravenous. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / radiography. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12445377.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Prodrugs; 0 / Topoisomerase I Inhibitors; 039LU44I5M / Floxuridine; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


55. Chronowski GM, Wilder RB, Tucker SL, Ha CS, Younes A, Fayad L, Rodriguez MA, Hagemeister FB, Barista I, Cabanillas F, Cox JD: Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. Int J Radiat Oncol Biol Phys; 2003 Jan 1;55(1):36-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy.
  • PURPOSE: We analyzed in-field (IF) control in adults with early-stage Hodgkin's disease who received chemotherapy followed by radiotherapy (RT) in terms of the (1) chemotherapeutic regimen used and number of cycles delivered, (2) response to chemotherapy, and (3) initial tumor size.
  • Cardiac toxicity and second malignancies, particularly the incidence of solid tumors in terms of the RT field size treated, were also examined.
  • METHODS AND MATERIALS: From 1980 to 1995, 286 patients ranging in age from 16 to 88 years (median: 28 years) with Ann Arbor clinical Stage I or II Hodgkin's disease underwent chemotherapy followed 3 to 4 weeks later by RT.
  • There were 516 nodal sites measuring 0.5 to 19.0 cm at the start of chemotherapy, including 134 cases of bulky mediastinal disease.
  • Patients received 1-8 (median: 3) cycles of induction chemotherapy.
  • All 533 gross nodal and extranodal sites of disease were included in the RT fields.
  • The median prescribed RT dose for gross disease was 40.0 Gy given in 20 daily 2.0-Gy fractions.
  • The chemotherapeutic regimen used and the number of cycles of chemotherapy delivered did not significantly affect IF control.
  • IF control also did not significantly depend on the response to induction chemotherapy.
  • In cases where there was a confirmed or unconfirmed complete response as opposed to a partial response or stable disease in response to induction chemotherapy for bulky nodal disease, the 5-year IF control rates were 99% and 92%, respectively (p = 0.0006).
  • The 15-year actuarial risks of coronary artery disease requiring surgical intervention and of solid tumors were 4.1% and 16.8%, respectively.
  • CONCLUSIONS: In patients with nonbulky disease, induction chemotherapy followed by RT to a median dose of 40.0 Gy resulted in excellent IF control, regardless of the chemotherapeutic regimen used, the fact that only 1-2 cycles of chemotherapy were delivered, and the response to chemotherapy.
  • Ongoing Phase III trials will help clarify whether lower RT doses and smaller RT fields after chemotherapy can maintain the IF control seen in our study, but with a lower incidence of late complications in patients with Stage I or II Hodgkin's disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hodgkin Disease / radiotherapy. Neoplasms, Second Primary / etiology. Radiotherapy / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Heart / drug effects. Heart / radiation effects. Humans. Male. Middle Aged. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Tomography, Emission-Computed

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12504034.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16672; United States / NCI NIH HHS / CA / CA 6294
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


56. Torre W, Sierra A: Postoperative complications of lung resection after induction chemotherapy using Paclitaxel (and radiotherapy) for advanced non-small lung cancer. J Cardiovasc Surg (Torino); 2002 Aug;43(4):539-44
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative complications of lung resection after induction chemotherapy using Paclitaxel (and radiotherapy) for advanced non-small lung cancer.
  • BACKGROUND: Locally advanced non-small-cell lung carcinoma is currently treated by multidisciplinary protocols using a combination of chemotherapy, radiotherapy and surgery.
  • However the best strategy for applying these therapeutic measures has not yet been established.
  • One of the difficulties of using these forms of treatment is their toxicity.
  • Our aim was to determine whether the postoperative course of the disease can be influenced by preoperative chemotherapy in any way.
  • METHODS: Nineteen patients were surgically treated after receiving induction treatment between October 1996 and October 1998.
  • The indications for giving induction treatment were: stage III disease in 12 patients (1 Pancoast tumor), lung cancer and solitary brain metastasis in 4 patients, double primary lung cancer in 3 patients (1 synchronous and 2 metachronous).
  • Variables were the chemotherapy treatment time interval from the beginning to surgery, the type of surgery, postoperative mortality and morbidity.
  • Neoadjuvant treatment consisted of chemotherapy in all patients (Paclitaxel, Cysplatin and Vinorelbine in cycles for a mean period of 3 months), and radiotherapy (14 patients).
  • CONCLUSIONS: Surgery for non-small-cell lung carcinoma has to be considered a high-risk procedure.
  • More studies are needed in order to define the exact role of these therapeutic measures.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Pneumonectomy. Postoperative Complications / etiology. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Cisplatin / administration & dosage. Female. Humans. Intraoperative Care. Male. Middle Aged. Paclitaxel / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12124570.001).
  • [ISSN] 0021-9509
  • [Journal-full-title] The Journal of cardiovascular surgery
  • [ISO-abbreviation] J Cardiovasc Surg (Torino)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


57. Gobbi PG, Broglia C, Levis A, La Sala A, Valentino F, Chisesi T, Sacchi S, Corbella F, Cavanna L, Iannitto E, Pavone V, Molica S, Corazza GR, Federico M: MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors. Clin Cancer Res; 2006 Jan 15;12(2):529-35
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
  • PURPOSE: MOPPEBVCAD (mechlorethamine, vincristine, procarbazine, prednisone, epidoxirubicin, bleomycin, vinblastine, lomustine, doxorubicin, and vindesine) chemotherapy with limited radiotherapy was devised in 1987 to reduce late toxicity and second tumor incidence while trying to improve effectiveness through increases of dose intensity and dose density.
  • Late results, toxicity, and second tumor incidence were reviewed in all the patients treated.
  • EXPERIMENTAL DESIGN: The drugs of three previous alternating regimens [CAD (lomustine, melphalan, and vindesine), MOPP (mechlorethamine, vincristine, procarbazine, and prednisone), and ABV (doxorubicin, bleomycin, and vinblastine)] were intensified and hybridized, the cumulative dose of mechlorethamine was lowered, and irradiation was delivered to no more than two sites either bulky or partially responding to chemotherapy.
  • RESULTS: A total of 307 previously untreated advanced-stage patients underwent MOPPEBVCAD chemotherapy.
  • With a median follow-up of 114 months, 10-year overall, disease-free, and failure-free survival rates were 79%, 84%, and 71%, respectively.
  • The causes of death were Hodgkin's lymphoma in 36 patients, second neoplasms in 12, cardiorespiratory diseases in 4, pulmonary diseases in 2, and unknown in 6.
  • Sixteen second tumors (of which nine were myelodysplasia and/or acute leukemia) were diagnosed in all.
  • CONCLUSIONS: Clinical response and long-term results are very satisfactory, whereas the second tumor incidence was lower than would have been expected with MOPP analogues.
  • Given its response/late toxicity balance, MOPPEBVCAD does not undermine the leading role of ABVD as first-line regimen but can be indicated as a very effective second-line conventional therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Bleomycin / toxicity. Combined Modality Therapy. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / toxicity. Drug-Related Side Effects and Adverse Reactions. Epirubicin / administration & dosage. Epirubicin / toxicity. Female. Humans. Lomustine / administration & dosage. Lomustine / toxicity. Male. Mechlorethamine / administration & dosage. Mechlorethamine / toxicity. Middle Aged. Pilot Projects. Prednisone / administration & dosage. Prednisone / toxicity. Procarbazine / administration & dosage. Procarbazine / toxicity. Survival Rate. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / toxicity. Vincristine / administration & dosage. Vincristine / toxicity. Vindesine / administration & dosage. Vindesine / toxicity

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16428496.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 3Z8479ZZ5X / Epirubicin; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7BRF0Z81KG / Lomustine; 80168379AG / Doxorubicin; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; CAD protocol 2; EBV protocol; MOPP protocol
  •  go-up   go-down


58. Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, Bayer L, LaFond D, Donahue BR, Marymont MH, Muraszko K, Langston J, Sposto R: Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol; 2006 Sep 1;24(25):4202-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.
  • METHODS: Four hundred twenty-one patients between 3 years and 21 years of age with nondisseminated medulloblastoma (MB) were prospectively randomly assigned to treatment with 23.4 Gy of CSRT, 55.8 Gy of posterior fossa RT, plus one of two adjuvant chemotherapy regimens: lomustine (CCNU), cisplatin, and vincristine; or cyclophosphamide, cisplatin, and vincristine.
  • EFS was unaffected by sex, race, age, treatment regimen, brainstem involvement, or excessive anaplasia.
  • There were seven second malignancies.
  • CONCLUSION: This study discloses an encouraging EFS rate for children with nondisseminated MB treated with reduced-dose craniospinal radiation and chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebellar Neoplasms / drug therapy. Cerebellar Neoplasms / radiotherapy. Medulloblastoma / drug therapy. Medulloblastoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant / adverse effects. Child. Child, Preschool. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Humans. Lomustine / administration & dosage. Male. Neoplasm Staging. Neoplasms, Second Primary / diagnosis. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Risk Factors. Survival Analysis. Vincristine / administration & dosage


59. Tsunezuka Y, Oda M, Moriyama H: [A case of a second cancer of metachronous multiple primary non-small cell lung cancer successfully treated with TS-1 and CDDP chemotherapy]. Gan To Kagaku Ryoho; 2006 May;33(5):651-3
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of a second cancer of metachronous multiple primary non-small cell lung cancer successfully treated with TS-1 and CDDP chemotherapy].
  • On November 2003, postoperative routine chest computed tomography(CT) demonstrated a mass in left S6, and pathological diagnosis revealed P/D squamous cell carcinoma (cT1N2M0, stage IIIA) by CT-guided needle biopsy and mediastinoscopy.
  • At first, we tried two courses of a combination chemotherapy consisting of carboplatin (CBDCA) and paclitaxel every 3 weeks.
  • The evaluation of the response was SD by the guidelines of Response Evaluation Criteria in Solid Tumor Groups.
  • Next, gefitinib was orally administered for 6 months but the tumor and mediastinal lymph nodes were growing.
  • The response was PR (the tumor decreased by 46%), no serious adverse effect was observed, and the patient maintained good quality of life throughout the chemotherapy.
  • This case suggests that TS-1+CDDP chemotherapy may be an effective treatment in patients with advanced lung cancer even after many protocols of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Lung Neoplasms / drug therapy. Neoplasms, Second Primary / drug therapy
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Administration, Oral. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Humans. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Neoplasm Staging. Oxonic Acid / administration & dosage. Pneumonectomy. Pyridines / administration & dosage. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16685165.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


60. Gollins S: Radiation, chemotherapy and biological therapy in the curative treatment of locally advanced rectal cancer. Colorectal Dis; 2010 Aug;12 Suppl 2:2-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation, chemotherapy and biological therapy in the curative treatment of locally advanced rectal cancer.
  • OBJECTIVE: To review the published evidence relating to the use of radiotherapy (RT), chemotherapy and biological therapy as adjuncts to surgery in the curative treatment of rectal cancer.
  • Internationally there is considerable heterogeneity in the staging modalities and criteria used in deciding which approach might be used, in the reporting of histological results and in RT parameters (time/dose/fractionation/volume).
  • The potential additional benefit of neoadjuvant or adjuvant chemotherapy in addition to SCPRT or long-course CRT remains ill-defined.
  • Late morbidity can include bowel and sexual dysfunction, pelvic fractures and second malignancies with considerably more being known in relation to SCPRT than long-course CRT.
  • CONCLUSIONS: Improvements in imaging, pathology and surgical technique combined with multimodality treatment using RT and chemotherapy are leading to continuing improvements in the long term outcome for patients with rectal cancer although much remains to be learnt regarding the optimum strategy for use of these in different clinical contexts and their relationship to long-term morbidity.
  • [MeSH-major] Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Biological Therapy. Combined Modality Therapy. Digestive System Surgical Procedures. Humans. Neoadjuvant Therapy. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Radiation-Sensitizing Agents / therapeutic use

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20618363.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Radiation-Sensitizing Agents
  •  go-up   go-down


61. Lyman GH, Dale DC, Wolff DA, Culakova E, Poniewierski MS, Kuderer NM, Crawford J: Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol; 2010 Jun 10;28(17):2914-24
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review.
  • PURPOSE: To evaluate the risk of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and overall mortality in patients receiving chemotherapy with or without granulocyte colony-stimulating factor (G-CSF), a systematic review of randomized controlled trials (RCTs) was conducted.
  • Eligibility included solid tumor or lymphoma patients randomly assigned to chemotherapy with or without G-CSF support, > or = 2 years of follow-up, and reporting AML/MDS or all second malignancies.
  • RESULTS: In the 25 eligible RCTs, 6,058 and 6,746 patients were randomly assigned to receive chemotherapy with and without initial G-CSF support, respectively.
  • Greater RR reduction for mortality was seen for both larger studies (P = .05) and greater chemotherapy dose-intensity (P = .012).
  • CONCLUSION: Delivered chemotherapy dose-intensity and risk of AML/MDS are increased but all-cause mortality is decreased in patients receiving chemotherapy with G-CSF support.
  • Greater reductions in mortality were observed with greater chemotherapy dose-intensity.
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Meta-Analysis as Topic. Randomized Controlled Trials as Topic. Treatment Outcome


62. Otsuka S, Inagaki M, Nishie M, Hamano R, Tokunaga N, Takahashi K, Tsunemitsu Y, Miyoshi K, Iwakawa K, Takahashi M, Iwagak H: [A case of pathological complete response of metachronous multiple liver metastases from colorectal cancer after mFOLFOX+bevacizumab chemotherapy]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2166-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pathological complete response of metachronous multiple liver metastases from colorectal cancer after mFOLFOX+bevacizumab chemotherapy].
  • A 25-year-old man with RS rectal cancer received a radical resection of the original tumor and lymph node dissection.
  • Oral tegafur/uracil (UFT)/Leucovorin (LV) therapy has been used for adjuvant chemotherapy, as the pathological Stage was T3N1M0, Stage IIIa.
  • So a systemic chemotherapy by mFOLFOX6+bevacizumab was begun via CV port.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colorectal Neoplasms / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / secondary

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037358.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 2S9ZZM9Q9V / Bevacizumab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


63. Bacci G, Longhi A, Barbieri E, Ferrari S, Mercuri M, Briccoli A, Versari M, Pignotti E, Picci P: Second malignancy in 597 patients with ewing sarcoma of bone treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999. J Pediatr Hematol Oncol; 2005 Oct;27(10):517-20
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancy in 597 patients with ewing sarcoma of bone treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999.
  • The relative risk of second tumors in patients with Ewing sarcoma is controversial, and little is known about their treatment and outcome.
  • The purpose of the current study was to define the incidence and features of second tumors among 597 long-term survivors of nonmetastatic Ewing sarcoma treated with adjuvant and neoadjuvant chemotherapy, radiotherapy, and/or surgery.
  • The authors found that the risk of secondary malignancy after adjuvant or neoadjuvant treatment of Ewing sarcoma is higher than that after other childhood or adolescent cancers only after radiotherapy.
  • [MeSH-major] Bone Neoplasms / pathology. Neoplasm Recurrence, Local / drug therapy. Neoplasms, Second Primary / pathology. Sarcoma, Ewing / pathology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Female. Humans. Male. Neoadjuvant Therapy. Survival Rate. Survivors. Treatment Outcome

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217253.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Toiyama Y, Inoue Y, Hiro J, Ojima E, Watanabe H, Miki C, Kusunoki M: Alteration of the chemoresistant gene expression during chemotherapy for colon cancer: a molecular case report. Oncol Rep; 2008 Mar;19(3):755-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alteration of the chemoresistant gene expression during chemotherapy for colon cancer: a molecular case report.
  • Chemotherapy remains the main choice of treatment for the management of unresectable or metastatic colorectal cancer.
  • However, drug resistance is a major problem, limiting the effectiveness of the chemotherapies presently used to treat cancer.
  • During treatment, drug resistance can also be acquired by tumors that are initially sensitive to chemotherapy.
  • We present a case of metachronous splenic recurrence after a curative resection of appendical cancer with ovarian metastasis, although the patient had been treated with 5-FU/LV followed by mFOLFOX6 after surgery.
  • Molecular analyses by RT-PCR also showed that the residual tumor after chemotherapy has cancer cells overexpressing 5-FU/l-OHP based chemotherapy-resistant genes.
  • Therefore, it was suggested that a careful assessment of the disease status be undertaken during chemotherapy to ensure that the possibility of surgical resection, especially of the re-growth or partial response tumors, was not missed, since several genes, chemoresistant to the agents used, can be induced in residual tumors during chemotherapy.
  • [MeSH-major] Colonic Neoplasms / drug therapy. Drug Resistance, Neoplasm / genetics
  • [MeSH-minor] Aged. Combined Modality Therapy. Enzymes / genetics. Enzymes / metabolism. Female. Humans. RNA, Messenger / metabolism. Splenic Neoplasms / pathology. Splenic Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18288412.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Enzymes; 0 / RNA, Messenger
  •  go-up   go-down


65. Yamaguchi K, Miyashita K, Asami S, Todoroki H, Saito Y, Daikoku Y: [Evaluation of intra-arterial infusion chemotherapy for liver metastases and lymph node metastases from gastric cancer--comparative analysis for intra-arterial group and non-intra-arterial group]. Gan To Kagaku Ryoho; 2001 Oct;28(11):1538-41
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of intra-arterial infusion chemotherapy for liver metastases and lymph node metastases from gastric cancer--comparative analysis for intra-arterial group and non-intra-arterial group].
  • We evaluated the effects of intra-arterial infusion chemotherapy for liver metastases and lymph node metastases of gastric cancer.
  • Intra-arterial infusion chemotherapy was carried out for 15 patients with liver metastases and 10 patients with lymph node metastases.
  • In a comparison between the intra-arterial and non-intra-arterial chemotherapy group, it was observed among the patients with synchronous liver metastases that the survival period of the intra-arterial group was significantly longer than that of the non-intra-arterial group (p = 0.0164 logrank test).
  • On the supposition that the survival period is counted from the day of computed tomography metachronous liver metastases was detected, in all liver metastases patients, the survival period of the intra-arterial group was significantly longer (p = 0.0212 logrank test).
  • These results showed that the intra-arterial infusion chemotherapy is a useful treatment for gastric cancer patients with liver metastases.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Liver Neoplasms / secondary. Lymph Nodes / pathology. Mitomycin / administration & dosage. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Angiotensin II / therapeutic use. Humans. Infusions, Intra-Arterial. Lymphatic Metastasis. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11707974.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11128-99-7 / Angiotensin II; 50SG953SK6 / Mitomycin
  •  go-up   go-down


66. Holsinger FC, Lin HY, Bassot V, Laccourreye O: Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx. Cancer; 2009 Sep 1;115(17):3909-18
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx.
  • BACKGROUND: The current study was conducted to determine the long-term outcomes of patients with squamous cell carcinoma of the larynx and pharynx who were treated with platin-based exclusive chemotherapy (EC) after they achieved a complete clinical response (CCR) to induction chemotherapy.
  • METHODS: One hundred forty-two who achieved a CCR after platin-based induction chemotherapy were treated exclusively with additional chemotherapy, and 98.6% were followed for a minimum of 3 years or until death.
  • The main causes of death were metachronous second primary tumors (n = 27) and intercurrent disease (n = 21).
  • In multivariate analysis, primary tumor arising outside the glottic larynx (P = .0001) and a Charlson comorbidity index >1 (P = .0001) were associated with a statistically significant reduction in survival.
  • Salvage treatment resulted in an observed final local control rate of 93% that varied from 97.2% in patients who had glottic cancer to 88.7% in patients who had tumor originating from other sites (P = .097).
  • Combined chemotherapy with cisplatin and 5-fluorouracil (PF) allowed for the successful modulation of local therapy in 54.9% of patients.
  • CONCLUSIONS: For selected patients, EC may provide long-term, durable disease control.
  • For patients who developed recurrent disease after EC, this approach did not diminish survival and maintained function in the majority of patients.
  • Future work should be directed toward select markers of response to PF chemotherapy with which to identify those patients who are suited optimally for this approach.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1983 Apr 15;51(8):1353-5 [6681726.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):327-33 [12525526.001]
  • [Cites] Head Neck Surg. 1983 Jul-Aug;5(6):500-7 [6885503.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] Cancer. 1987 Sep 15;60(6):1178-83 [3304610.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] J Natl Cancer Inst. 1994 Feb 16;86(4):265-72 [8158680.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):83-91 [7819055.001]
  • [Cites] Head Neck. 1995 Sep-Oct;17(5):377-81 [8522437.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):838-47 [8622032.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2331-6 [8708725.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Lancet Oncol. 2006 Jul;7(7):565-74 [16814208.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):570-80 [16899777.001]
  • [Cites] J Laryngol Otol. 2007 Feb;121(2):143-8 [17005065.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1143-54 [18784104.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Laryngoscope. 2000 Jan;110(1):58-64 [10646717.001]
  • [Cites] Head Neck. 2004 Apr;26(4):365-72 [15054740.001]
  • [Cites] Br J Cancer. 2000 Dec;83(12):1594-8 [11189100.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1504-11 [11745228.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • (PMID = 19551883.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K12 CA88084; United States / NCI NIH HHS / CA / K12 CA088084-09; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA097007; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / K12 CA088084; United States / NCI NIH HHS / CA / P50 CA97007
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Platinum Compounds; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ NIHMS124415; NLM/ PMC3851301
  •  go-up   go-down


67. Karanjia ND, Lordan JT, Fawcett WJ, Quiney N, Worthington TR: Survival and recurrence after neo-adjuvant chemotherapy and liver resection for colorectal metastases: a ten year study. Eur J Surg Oncol; 2009 Aug;35(8):838-43
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and recurrence after neo-adjuvant chemotherapy and liver resection for colorectal metastases: a ten year study.
  • We prospectively audited the outcome of CRLM treated by a combination of neo-adjuvant chemotherapy and surgery.
  • Patients received chemotherapy preoperatively for synchronous and early (< 2 years) metachronous metastases.
  • Disease free survival at 1, 3 and 5 years was 68.1%, 34.8% and 27.9%, respectively.
  • Incidence of CIRM and re-resection was 4.9% and 4.5%, respectively.
  • CONCLUSIONS: Neo-adjuvant chemotherapy followed by liver surgery is associated with improved survival and low CIRM and re-resection rates.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Colorectal Neoplasms / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery. Neoplasm Recurrence, Local
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hepatectomy. Humans. Male. Middle Aged. Neoadjuvant Therapy. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19010633.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


68. Clamp AR, Ryder WD, Bhattacharya S, Pettengell R, Radford JA: Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma. Br J Cancer; 2008 Jul 22;99(2):253-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma.
  • The effect of utilising granulocyte colony-stimulating factor (G-CSF) to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma (NHL) on long-term mortality patterns has not been formally evaluated.
  • Data on 10-year overall survival (OS), progression-free survival (PFS), freedom from progression (FFP) and incidence of second malignancies were collected for 80 patients with aggressive subtypes of NHL, who had been randomised to receive either VAPEC-B chemotherapy or VAPEC-B+G-CSF.
  • Eleven deaths from causes unrelated to NHL or its treatment occurred in the G-CSF arm compared to five in controls.
  • More deaths occurred from second malignancies (4 vs 2) and cardiovascular causes (5 vs 0) in the G-CSF arm.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Middle Aged. Proportional Hazards Models. Survival Rate. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1997 Jun 1;89(11):3974-9 [9166835.001]
  • [Cites] Leuk Lymphoma. 1994 Sep;15(1-2):153-7 [7532056.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7801-12 [15520186.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2912-9 [16339404.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1568-74 [16520465.001]
  • [Cites] Cardiovasc Drugs Ther. 2006 Apr;20(2):85-91 [16761189.001]
  • [Cites] Haematologica. 2006 Nov;91(11):1481-8 [17043014.001]
  • [Cites] J Natl Cancer Inst. 2007 Feb 7;99(3):196-205 [17284714.001]
  • [Cites] J Natl Cancer Inst. 2007 Feb 7;99(3):206-14 [17284715.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] Prog Cardiovasc Dis. 2007 Mar-Apr;49(5):330-52 [17329180.001]
  • [Cites] Am J Pathol. 1999 Nov;155(5):1557-67 [10550313.001]
  • [Cites] Blood. 2003 May 15;101(10):3840-8 [12531794.001]
  • [Cites] Blood. 2003 May 15;101(10):3862-7 [12531808.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3041-50 [12915593.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1222-8 [14576060.001]
  • [Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]
  • [Cites] Blood. 2004 Aug 1;104(3):634-41 [15016643.001]
  • [Cites] Cochrane Database Syst Rev. 2004;(3):CD003189 [15266474.001]
  • [Cites] Cancer Treat Rep. 1983 Oct;67(10):923-31 [6627236.001]
  • [Cites] Blood. 1992 Sep 15;80(6):1430-6 [1381626.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Blood. 1993 Oct 15;82(8):2329-39 [7691256.001]
  • [Cites] J Natl Cancer Inst. 1993 Dec 1;85(23):1932-7 [8230284.001]
  • [Cites] Ann Oncol. 1994;5 Suppl 2:123-5 [7515644.001]
  • [Cites] Leuk Lymphoma. 1997 Apr;25(3-4):289-300 [9168439.001]
  • (PMID = 18594529.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VAPEC-B protocol
  • [Other-IDs] NLM/ PMC2480980
  •  go-up   go-down


69. Pico C, Martin M, Jara C, Barnadas A, Pelegri A, Balil A, Camps C, Frau A, Rodriguez-Lescure A, Lopez-Vega JM, De La Haba J, Tres A, Alvarez I, Alba E, Arcusa A, Oltra A, Batista N, Checa T, Perez-Carrion R, Curto J, GEICAM Group: Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. Ann Oncol; 2004 Jan;15(1):79-87
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study.
  • BACKGROUND: A prospective randomized clinical trial was implemented to assess whether the concomitant or the sequential addition of tamoxifen to chemotherapy provides improved clinical benefit in the adjuvant treatment of breast cancer in postmenopausal patients.
  • PATIENTS AND METHODS: Four-hundred and eighty-five patients with node-positive operable disease were randomized to receive tamoxifen (20 mg/day) concomitantly (CON) or sequentially (SEQ) to EC chemotherapy (epirubicin 75 mg/m(2) + cyclophosphamide 600 mg/m(2) on day 1, every 21 days for four cycles).
  • RESULTS: In the 474 fully evaluable patients there were 96 events; eight being second neoplasms and 88 being related to the breast cancer.
  • The Kaplan-Meier estimation of disease-free survival (DFS) at 5 years was 70% in the CON and 75% in the SEQ group (log-rank test, P = 0.43).
  • Adjusted hazard ratio for treatment was 1.11 (95% confidence interval 0.71-1.73; P = 0.64).
  • CONCLUSION: This study fails to show an advantage of one treatment arm over the other, but a trend, albeit non-significant, appears to favor the sequential addition of tamoxifen to epirubicin + cyclophosphamide and, as such, warrants further investigation.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14679124.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


70. Kopjar N, Garaj-Vrhovac V, Milas I: Assessment of chemotherapy-induced DNA damage in peripheral blood leukocytes of cancer patients using the alkaline comet assay. Teratog Carcinog Mutagen; 2002;22(1):13-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of chemotherapy-induced DNA damage in peripheral blood leukocytes of cancer patients using the alkaline comet assay.
  • The alkaline comet assay was employed to assess the pre- and post-treatment levels of in vivo DNA damage in peripheral blood leukocytes of cancer patients.
  • During the study all patients were given antineoplastic drugs, mainly as polychemotherapy.
  • Our results indicate marked interindividual variations between baseline DNA damage in peripheral blood leukocytes recorded among cancer patients prior to the chemotherapy.
  • After intravenous administration of various antineoplastic drugs, a significantly increased level of DNA damage in all cancer patients compared to their pre-treatment values was recorded The highest level of DNA damage was seen following administration of 5-fluorouracil, adriamycin, and cisplatin (FAP protocol).
  • The results indicate that administration of antineoplastic drugs in standard protocols is accompanied by significant DNA damage in peripheral blood leukocytes.
  • In order to diminish the potential risks of developing second neoplasms, a continuous biomonitoring of cancer patients after the ending of chemotherapy becomes important.
  • Despite their limitations, present results confirm the usefulness of the alkaline comet assay as a sensitive biomarker of exposure that enables rapid and simple detection of primary DNA damage in peripheral blood leukocytes of cancer patients.
  • Together with standard cytogenetic endpoints, the comet assay provides a powerful technique for the routine detection of critical DNA lesions produced after administration of antineoplastic drugs in the clinical settings.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Comet Assay / methods. DNA Damage / drug effects. DNA, Neoplasm / drug effects. Lymphocytes / drug effects
  • [MeSH-minor] Adult. DNA Repair. Female. Humans. Male. Middle Aged. Neoplasms / drug therapy. Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 11754384.001).
  • [ISSN] 0270-3211
  • [Journal-full-title] Teratogenesis, carcinogenesis, and mutagenesis
  • [ISO-abbreviation] Teratog., Carcinog. Mutagen.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


71. Dobson LS, Lorigan PC, Coleman RE, Hancock BW: Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease. Br J Cancer; 2000 May;82(9):1547-52
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease.
  • Persistent gestational trophoblastic disease is potentially fatal, but the majority of patients are cured with chemotherapy.
  • Any developments in treatment are therefore being directed towards maintaining efficacy and reducing toxicity.
  • We evaluated efficacy and toxicity of methotrexate, etoposide and dactinomycin (MEA) as first-line therapy for high risk disease and etoposide and dactinomycin (EA) as second-line therapy for methotrexate-refractory low risk disease in a retrospective analysis of 73 patients (38 MEA, 35 EA) treated since 1986 at a supra-regional centre.
  • Of eight patients who failed to respond, four have since died and four were cured with platinum-based chemotherapy.
  • No patient has developed a second malignancy.
  • In conclusion, the MEA and EA chemotherapy regimens for persistent trophoblastic disease are very well tolerated, do not appear to affect future fertility and are associated with excellent, sustained complete response rates.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Trophoblastic Neoplasms / drug therapy. Uterine Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 1973 Feb 15;115(4):451-7 [4346614.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1270-2 [10098770.001]
  • [Cites] Br J Obstet Gynaecol. 1986 Jan;93(1):63-9 [3002420.001]
  • [Cites] Obstet Gynecol. 1987 Mar;69(3 Pt 1):390-5 [3029641.001]
  • [Cites] Br J Obstet Gynaecol. 1989 Jul;96(7):795-802 [2548568.001]
  • [Cites] Br J Obstet Gynaecol. 1991 Jun;98(6):550-7 [1651757.001]
  • [Cites] Gynecol Oncol. 1992 Apr;45(1):40-5 [1318254.001]
  • [Cites] J Reprod Med. 1992 May;37(5):461-5 [1324312.001]
  • [Cites] Obstet Gynecol. 1994 Jan;83(1):113-7 [8272290.001]
  • [Cites] Gynecol Oncol. 1994 Jul;54(1):76-9 [8020843.001]
  • [Cites] J Reprod Med. 1994 Mar;39(3):217-22 [7518518.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 1994 Feb;34(1):90-2 [8053886.001]
  • [Cites] Semin Oncol. 1995 Apr;22(2):157-60 [7740316.001]
  • [Cites] Semin Oncol. 1995 Apr;22(2):161-5 [7740317.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2636-43 [9215835.001]
  • [Cites] Cancer. 1976 Sep;38(3):1373-85 [182354.001]
  • (PMID = 10789722.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] SCOTLAND
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 6PLQ3CP4P3 / Etoposide; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC2363400
  •  go-up   go-down


72. Shen P, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA, Levine EA: Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol; 2004 Feb;11(2):178-86
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma.
  • BACKGROUND: Cytoreductive surgery (CS) and intraperitoneal hyperthermic chemotherapy (IPHC) are efficacious in patients with disseminated mucinous tumors of the appendix.
  • METHODS: We performed a retrospective chart review of a prospective database for patients undergoing CS and IPHC with mitomycin C for peritoneal carcinomatosis from colorectal primary lesions between December 1991 and April 2002.
  • Peritoneal carcinomatosis was synchronous and metachronous in 27% and 73% patients, respectively.
  • Seventy-five percent of patients (n = 58) had received chemotherapy prior to IPHC.
  • Complete resection of all gross disease was accomplished in 37 patients (48%).
  • Cox regression analysis identified poor performance status (P =.018), bowel obstruction (P =.001), malignant ascites (P =.001), and incomplete resection of gross disease (P =.011) as independent predictors of decreased survival.
  • Patients with complete resection of all gross disease had a 5-year OS of 34%, with a median OS of 28 months.
  • One third of patients who undergo complete resection of gross disease have long-term survival.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Carcinoma / drug therapy. Carcinoma / surgery. Colorectal Neoplasms / pathology. Hyperthermia, Induced. Mitomycin / administration & dosage. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Disease-Free Survival. Female. Humans. Infusions, Parenteral. Male. Middle Aged. Multivariate Analysis. Proportional Hazards Models. Retrospective Studies. Survival Rate. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2004 Feb;11(2):122-3 [14761912.001]
  • (PMID = 14761921.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


73. Laccourreye O, Veivers D, Hans S, Ménard M, Brasnu D, Laccourreye H: Chemotherapy alone with curative intent in patients with invasive squamous cell carcinoma of the pharyngolarynx classified as T1-T4N0M0 complete clinical responders. Cancer; 2001 Sep 15;92(6):1504-11
Hazardous Substances Data Bank. PLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy alone with curative intent in patients with invasive squamous cell carcinoma of the pharyngolarynx classified as T1-T4N0M0 complete clinical responders.
  • BACKGROUND: The current studies documented the results achieved with chemotherapy alone with curative intent in a series of 67 patients with invasive squamous cell carcinoma of the pharyngolarynx classified as T1-T4N0M0 complete clinical responders after a platin-based induction chemotherapy regimen.
  • Statistical analyses of survival, local control, lymph node control, distant metastasis, and second primary tumor rates were based on the Kaplan-Meier life-table method.
  • Local control rates after salvage treatment were 100% in Group I patients and 83% in Group II patients.
  • Laryngeal preservation rates after salvage treatment were 100% in Group I patients and 64% in Group II patients.
  • The 10-year actuarial estimate for patients without metachronous second primary tumors was 56.4% in Group I and 46.1% in Group II.
  • CONCLUSIONS: The current report 1) contradicts the old dogma of nonchemocurability for invasive squamous cell carcinoma of the upper aerodigestive tract and 2) suggests that the use of a platin-based chemotherapy-alone regimen with curative intent in patients with invasive squamous cell carcinoma of the pharyngolarynx who are classified as T1-T4N0M0 complete clinical responders after receiving an induction chemotherapy regimen is best indicated when the tumor originates from the glottis.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Laryngeal Neoplasms / drug therapy. Pharyngeal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Drug Therapy, Combination. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasms, Second Primary. Platinum / administration & dosage. Salvage Therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11745228.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 49DFR088MY / Platinum; U3P01618RT / Fluorouracil
  •  go-up   go-down


74. Rubino C, de Vathaire F, Shamsaldin A, Labbe M, Lê MG: Radiation dose, chemotherapy, hormonal treatment and risk of second cancer after breast cancer treatment. Br J Cancer; 2003 Sep 1;89(5):840-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation dose, chemotherapy, hormonal treatment and risk of second cancer after breast cancer treatment.
  • In total, 281 of the 7711 women who were initially treated for breast cancer between 1954 and 1983 at the Gustave Roussy Institute developed a second malignant neoplasm (SMN) other than second primary breast cancer and nonmelanoma skin cancer at least 1 year after breast cancer treatment.
  • In the irradiated patients, the median local dose was higher among cases (3.1 Gy) than among controls (1.3 Gy).
  • More than 40% of the irradiated patients received a local dose of less than 1 Gy.
  • According to the quadratic model, the excess risk of SMN was 0.2% (95% CI 0.05-0.5%) when the target organ received 1 Gy.
  • This risk did not differ significantly according to age at the time of radiotherapy (<40 vs >or=40 years).
  • The risk of SMN was 6.7-fold higher for doses of 25 Gy or more than in the absence of radiotherapy.
  • No carcinogenic effect of chemotherapy was observed and a dose-effect relationship between the length of tamoxifen treatment and SMN occurrence was found.
  • Our results suggest that high radiation doses slightly increase the risk of second malignancies after breast cancer.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / adverse effects. Case-Control Studies. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Drug-Related Side Effects and Adverse Reactions. Female. Humans. Logistic Models. Middle Aged. Radiotherapy / adverse effects. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 May 20;355(9217):1757-70 [10832826.001]
  • [Cites] Radiother Oncol. 1996 Mar;38(3):269-71 [8693110.001]
  • [Cites] Ann Oncol. 1996 Mar;7(3):239-44 [8740786.001]
  • [Cites] Lancet. 1998 May 16;351(9114):1451-67 [9605801.001]
  • [Cites] J Gynecol Obstet Biol Reprod (Paris). 1998 Sep;27(5):501-7 [9791576.001]
  • [Cites] Radiother Oncol. 1998 Oct;49(1):85-90 [9886702.001]
  • [Cites] Breast Cancer Res Treat. 1999 Feb;53(3):271-7 [10369073.001]
  • [Cites] Ann Oncol. 2000 Dec;11(12):1537-43 [11205460.001]
  • [Cites] Jpn J Cancer Res. 2001 Jan;92(1):1-8 [11173537.001]
  • [Cites] Int J Radiat Biol. 2001 Apr;77(4):431-64 [11304437.001]
  • [Cites] N Engl J Med. 2002 Oct 17;347(16):1227-32 [12393819.001]
  • [Cites] Breast Cancer Res Treat. 2002 Sep;75(1):15-24 [12500931.001]
  • [Cites] IARC Sci Publ. 1980;(32):5-338 [7216345.001]
  • [Cites] Natl Cancer Inst Monogr. 1985 Dec;68:99-112 [4088315.001]
  • [Cites] Am J Clin Oncol. 1986 Jun;9(3):269-75 [3755282.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1138-42 [3625243.001]
  • [Cites] Jpn J Clin Oncol. 1987 Dec;17(4):293-302 [3694826.001]
  • [Cites] Lancet. 1989 Jan 21;1(8630):117-20 [2563046.001]
  • [Cites] Cancer. 1990 Sep 1;66(5):874-81 [2386915.001]
  • [Cites] J Natl Cancer Inst. 1991 Jul 17;83(14):1013-7 [2072407.001]
  • [Cites] Acta Oncol. 1992;31(2):259-63 [1622643.001]
  • [Cites] J Clin Oncol. 1994 Mar;12(3):447-53 [8120544.001]
  • [Cites] World J Surg. 1994 Jan-Feb;18(1):63-9 [8197778.001]
  • [Cites] Ann Oncol. 1994 Nov;5(9):803-8 [7848882.001]
  • [Cites] J Natl Cancer Inst. 1995 May 3;87(9):645-51 [7752269.001]
  • [Cites] J Natl Cancer Inst. 1996 Jun 19;88(12):832-4 [8637050.001]
  • [Cites] Breast Cancer Res Treat. 2000 Jun;61(3):183-95 [10965995.001]
  • (PMID = 12942115.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  • [Other-IDs] NLM/ PMC2394476
  •  go-up   go-down


75. Usui N, Yano S, Asai O, Dobashi N, Osawa H, Takei Y, Sugiyama K, Takahara S, Otubo H, Saito T, Okawa Y, Hagino T, Kaito K, Kobayashi M: Long-term follow-up high-dose chemotherapy (drug-only program) followed by autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas. Clin Lymphoma; 2005 Jun;6(1):31-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up high-dose chemotherapy (drug-only program) followed by autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas.
  • PURPOSE: To investigate the feasibility of high-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) for aggressive non-Hodgkin's lymphoma (NHL), we conducted HDCT with ASCT using a drug-only protocol without total body irradiation.
  • For the HDCT protocol, we developed the AECC regimen, a drug-only regimen consisting of etoposide, carboplatin, cyclophosphamide, and nimustine (ie, ACNU).
  • RESULTS: Before HDCT, 37 patients still had disease (26 partial responses [PRs] and 11 cases of no response), and 19 patients exhibited a complete response (CR) before HDCT with ASCT.
  • Among 56 patients, 37 (66%) exhibited a CR, including patients continuing their first CR and those experiencing a second or further CR, and 11 patients (19.6%) exhibited PR on HDCT with ASCT.
  • No patients developed a second malignancy, including leukemia or myelodysplastic syndrome.
  • CONCLUSIONS: High-dose chemotherapy followed by ASCT is one of the available consolidation therapies for aggressive NHL, and additional involved-field irradiation could play a role in the management of patients with NHL who do not exhibit a CR after treatment with HDCT containing a drug-only program.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Lymphoma, Non-Hodgkin / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Humans. Male. Middle Aged. Prednisone / therapeutic use. Survival Analysis. Transplantation, Autologous. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15989704.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


76. Peterson BA, Petroni GR, Frizzera G, Barcos M, Bloomfield CD, Nissen NI, Hurd DD, Henderson ES, Sartiano GP, Johnson JL, Holland JF, Gottlieb AJ: Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol; 2003 Jan 1;21(1):5-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B.
  • PURPOSE: The array of options for the initial management of follicular small cleaved lymphoma (FSCL) and follicular mixed lymphoma (FML) ranges from little or no therapy to the use of intensive combinations of drugs.
  • The Cancer and Leukemia Group B (CALGB) compared two contrasting approaches: a single agent, and combination chemotherapy capable of curing diffuse aggressive lymphomas.
  • Treatment was continued in responders for 2 years beyond maximal response.
  • The primary end point was survival in the most common subtype, FSCL.
  • At 10 years with either cyclophosphamide or CHOP-B, respectively, overall time to failure (25% failure free v 33%; P =.107) and survival (44% alive v 46%; P =.79) were similar by treatment.
  • Acute toxic effects were more common with combination chemotherapy.
  • Second malignancies, which might be attributed to treatment, were seen with both approaches.
  • However, in an unplanned subgroup analysis, patients with FML who received the combination experienced improved disease control and survival.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Lymphoma, Follicular / drug therapy. Prednisone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Regression Analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2003 Jan 1;21(1):1-2 [12506161.001]
  • (PMID = 12506163.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP-B protocol
  •  go-up   go-down


77. Maniar TN, Braunstein I, Keefe S, Hussen S, Abrams T, De Michele A, El-Deiry WS: Childhood ALL and second neoplasms. Cancer Biol Ther; 2007 Oct;6(10):1525-31
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood ALL and second neoplasms.
  • Second malignancies are a significant concern for survivors of childhood acute lymphoblastic leukemia (ALL), in particular patients who have been treated with cranial irradiation.
  • Brain tumors, most commonly meningiomas, are among the most common second neoplasms discovered in these patients.
  • Breast cancer can occur in association with meningioma, but is not thought to be a consequence of treatment for childhood ALL.
  • We describe the molecular genetics and therapy of childhood ALL, the molecular genetics of meningioma, as well as the possible association between meningioma and breast cancer.
  • [MeSH-major] Breast Neoplasms / epidemiology. Meningeal Neoplasms / epidemiology. Meningioma / epidemiology. Neoplasms, Second Primary / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17952026.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 96
  •  go-up   go-down


78. Cardous-Ubbink MC, Heinen RC, Bakker PJ, van den Berg H, Oldenburger F, Caron HN, Voûte PA, van Leeuwen FE: Risk of second malignancies in long-term survivors of childhood cancer. Eur J Cancer; 2007 Jan;43(2):351-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of second malignancies in long-term survivors of childhood cancer.
  • INTRODUCTION: Childhood cancer survivors are known to be at increased risk for second malignancies.
  • PATIENTS AND METHODS: The risk of second malignancies was assessed in 1368 5-year survivors of childhood cancer treated in the Emma Children's Hospital AMC in Amsterdam.
  • The median follow-up time was 16.8 years.
  • RESULTS: Sixty two malignancies were observed against 5.4 expected, yielding a standardised incidence ratio (SIR) of 11.2 (95% confidence interval: 8.53-14.4; absolute excess risk: 3.2 per 1000 person-years).
  • Patients whose treatment involved radiotherapy had a 2-fold increased second cancer risk compared to patients with chemotherapy alone.
  • DISCUSSION: The relative risk of second malignancies does not decrease till at least 30 years of follow-up.
  • [MeSH-major] Neoplasms, Second Primary / etiology. Survivors / statistics & numerical data

  • Genetic Alliance. consumer health - Childhood Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17141498.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


79. Song DY, Jones RJ, Welsh JS, Haulk TL, Korman LT, Noga S, Goodman S, Herman M, Mann R, Marcellus D, Vogelsang G, Ambinder RF, Abrams RA: Phase I study of escalating doses of low-dose-rate, locoregional irradiation preceding Cytoxan-TBI for patients with chemotherapy-resistant non-Hodgkin's or Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys; 2003 Sep 1;57(1):166-71
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of escalating doses of low-dose-rate, locoregional irradiation preceding Cytoxan-TBI for patients with chemotherapy-resistant non-Hodgkin's or Hodgkin's lymphoma.
  • PURPOSE: In patients in whom bone marrow transplantation (BMT) fails, recurrence often occurs at sites known to have contained disease before initiating BMT.
  • The purpose of this study was to find the maximal tolerable dose of locoregional irradiation (LRT) between 1000 and 2000 cGy that could be integrated with our Cytoxan-total body irradiation (TBI) BMT conditioning regimen in the treatment of lymphoma.
  • METHODS AND MATERIALS: Patients had Hodgkin's or non-Hodgkin's lymphoma in chemotherapy-refractory relapse.
  • All patients received LRT to a maximum of three sets of fields encompassing either all current or all previously known sites of disease.
  • Radiation Therapy Oncology Group Grade 3 in-field acute toxicity was observed in 1 patient at each dose level up to 1500 cGy and in 3 of 6 patients receiving 2000 cGy.
  • Clinically evident late toxicities were limited to hypothyroidism and one second malignancy occurring outside the LRT fields.
  • This regimen safely permits the use of a total combined radiation dose of up to 2700 cGy during 2 weeks, with encouraging in-field response rates in treatment-refractory patients.
  • [MeSH-major] Cyclophosphamide / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Maximum Tolerated Dose. Whole-Body Irradiation / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Marrow Transplantation. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Dose-Response Relationship, Radiation. Humans. Middle Aged. Radiotherapy Dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12909229.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


80. Miser JS, Goldsby RE, Chen Z, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore SG, Rausen AR, Vietti TJ, Grier HE: Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy--a report from the Children's Oncology Group. Pediatr Blood Cancer; 2007 Dec;49(7):894-900
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy--a report from the Children's Oncology Group.
  • BACKGROUND: The outcome for patients with Ewing sarcoma family of tumors (ESFTs) of bone with metastases at diagnosis remains poor despite new approaches to treatment.
  • We evaluated whether a dose-intensity chemotherapy regimen improved survival for patients with ESFTs of bone with metastases at diagnosis.
  • METHODS: We entered 60 patients with metastatic ESFTs of bone onto a single arm trial of a new intensive therapy.
  • Treatment consisted of 51-weeks of chemotherapy and local control of the primary with radiation, surgery, or both.
  • The chemotherapeutic protocol included two alternating blocks: one with vincristine (2 mg/m(2)), doxorubicin (90 mg/m(2)), and cyclophosphamide (2,200 mg/m(2)); and the second with ifosfamide (2,800 mg/m(2)/day x 5 days) and etoposide (100 mg/m(2)/day x 5 days).
  • Six patients (6-year cumulative incidence: 9%) developed second malignant neoplasms and died.
  • The 6-year overall event-free survival (EFS) was 28% (standard error (SE) 6%) and survival (S) was 29% (SE 6%).
  • CONCLUSION: An intensified treatment regimen using higher doses of cyclophosphamide, ifosfamide, and doxorubicin increased toxicity and risk of second malignancy without improving EFS and S.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bone Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Neoplasms, Second Primary / chemically induced. Neuroectodermal Tumors, Primitive / therapy. Sarcoma, Ewing / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Critical Care. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infant. Injections, Subcutaneous. Male. Risk Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • (PMID = 17584910.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA 13539; United States / NCI NIH HHS / CA / U10 CA 30969; United States / NCI NIH HHS / CA / U10 CA 98543
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


81. Liu MC, Demetri GD, Berry DA, Norton L, Broadwater G, Robert NJ, Duggan D, Hayes DF, Henderson IC, Lyss A, Hopkins J, Kaufman PA, Marcom PK, Younger J, Lin N, Tkaczuk K, Winer EP, Hudis CA, Cancer and Leukemia Group B: Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treat Rev; 2008 May;34(3):223-30
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.
  • PURPOSE: To assess the safety, tolerability, and clinical outcomes of an adjuvant chemotherapy regimen designed to incorporate a non-cross-resistant agent (paclitaxel, T) with a maximally dose-intensified regimen of doxorubicin and cyclophosphamide (AC) in conjunction with hematopoietic growth factor support (recombinant human granulocyte-colony stimulating factor; G-CSF; Filgrastim).
  • The protocol treatment comprised five cycles of dose-intensified AC (75 and 2000 mg/m(2)/cycle, respectively, intravenously every three weeks) with G-CSF support, followed by an additional four cycles of T (175 mg/m(2) by 3h intravenous infusion, every three weeks).
  • Patients were randomized to receive one of two dose levels of G-CSF (5 vs. 10 mcg/kg/day) during AC chemotherapy.
  • RESULTS: One hundred and seventy two node-positive patients with operable primary breast cancer were accrued to this trial between February 1993 and April 1994.
  • 130 of the 172 patients (76%) completed all protocol-specified therapy.
  • Of the 42 early study withdrawals, 23 were due to unacceptable acute treatment-related toxicity.
  • Ten patients developed second malignancies during follow-up, including three cases with a hematologic malignancy (2% incidence).
  • The data confirmed the acceptable tolerability of T after aggressive myelotoxic therapy in the adjuvant setting, leading to a larger randomized clinical trial comparing three dose levels of doxorubicin in AC with or without the addition of T (CALGB 9344).
  • Supportive care using twice the conventional dose of G-CSF did not significantly improve the tolerability or change the toxicities of this regimen, and the occurrence of secondary malignancies is consistent with the emerging risk profile of dose-intensive regimens with growth factor support.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3374-88 [10550131.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1673-84 [16236738.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1431-9 [12668651.001]
  • [Cites] Am J Med. 1980 Oct;69(4):585-94 [6999898.001]
  • [Cites] J Clin Oncol. 1984 Nov;2(11):1281-8 [6387060.001]
  • [Cites] J Clin Oncol. 1985 Dec;3(12):1640-58 [3906049.001]
  • [Cites] J Clin Oncol. 1988 Sep;6(9):1501-15 [3047340.001]
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1483-96 [2202791.001]
  • [Cites] J Natl Cancer Inst. 1991 Dec 18;83(24):1797-805 [1683908.001]
  • [Cites] Semin Oncol. 1993 Aug;20(4 Suppl 3):40-5 [7688145.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1253-9 [8080512.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1858-69 [9164196.001]
  • [Cites] J Natl Cancer Inst. 1998 Aug 19;90(16):1205-11 [9719081.001]
  • [Cites] Lancet. 1998 Sep 19;352(9132):930-42 [9752815.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1413-24 [10334526.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5542-51 [16110015.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1659-72 [16236737.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):976-83 [12637460.001]
  • (PMID = 18234424.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA047577; United States / NCI NIH HHS / CA / U10 CA032291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA031946-27; United States / NCI NIH HHS / CA / U10 CA035279; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / U10 CA047642; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / U10 CA003927; United States / NCI NIH HHS / CA / U10 CA031946-27
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel; PVI5M0M1GW / Filgrastim
  • [Other-IDs] NLM/ NIHMS52349; NLM/ PMC2651678
  •  go-up   go-down


82. Sakaguchi H, Aizawa K, Muramatsu S, Matsushita A, Kumaki T, Kasuga Y: [A case of recurrence with liver metastasis after total gastrectomy for StageIA gastric carcinoma successfully treated with S-1/CDDP combination followed by S-1 chemotherapy]. Gan To Kagaku Ryoho; 2010 Jun;37(6):1121-3
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrence with liver metastasis after total gastrectomy for StageIA gastric carcinoma successfully treated with S-1/CDDP combination followed by S-1 chemotherapy].
  • One year after operation, abdominal CT revealed a metastatic tumor in the left lateral posterior segment of the liver.
  • He was given S-1/ CDDP combination chemotherapy(S-1 120mg/body, day 1-21, CDDP 95mg/body, day 8)every 5weeks as first-line treatment.
  • After 2 courses of the treatment, the liver tumor was not detected by PET-CT.
  • After total 5 courses of the treatment, we changed to a single administration of S-1(120mg/body, day 1- 14)every 3 or 4 weeks as second-line chemotherapy.
  • S-1/CDDP and S-1 chemotherapy are effective for metachronous liver metastasis from gastric carcinoma, although prognosis of the disease is poor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Liver Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Combinations. Gastrectomy. Humans. Male. Neoplasm Staging. Positron-Emission Tomography. Recurrence. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20567120.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


83. Shim KW, Kim DS, Choi JU: Mixed or metachronous germ-cell tumor? Childs Nerv Syst; 2007 Jun;23(6):713-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed or metachronous germ-cell tumor?
  • OBJECTIVE AND IMPORTANCE: We report the extremely rare occurrence of a second germ-cell tumor at a different site and with different histological types long after total resolution of a pineal germinoma.
  • Neuroradiological studies revealed a tumor in the pineal region.
  • The tumor was biopsied with endoscope, and third ventriculostomy was performed.
  • Histologically, the tumor proved to be a germinoma.
  • The patient received 3 cycles of combination chemotherapy consisting of carboplatin and etoposide with radiotherapy.
  • The tumor was totally resolute.
  • Neuroradiological studies showed a tumor in the right temporal lobe.
  • INTERVENTION: The second tumor was totally removed.
  • Histologically, the tumor proved to be a mixed germ-cell tumor, which consisted a yolk-sac tumor and a germinoma.
  • After the second course of chemotherapy, magnetic resonance image studies revealed no evidence of the tumor.
  • CONCLUSION: The second tumor was considered to be a metachronous neoplasm rather than a recurrence of the original mixed germ-cell tumor, which consisted a yolk-sac tumor and a germinoma.
  • [MeSH-major] Brain Neoplasms / pathology. Endodermal Sinus Tumor / pathology. Germinoma / pathology. Neoplasms, Multiple Primary / pathology. Pinealoma / pathology. Temporal Lobe / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1985 Aug;63(2):155-67 [2991485.001]
  • [Cites] J Neurosurg. 1983 Nov;59(5):879-83 [6619943.001]
  • [Cites] Neurosurgery. 2002 Mar;50(3):613-6; discussion 616-7 [11841731.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):229-45 [8270446.001]
  • [Cites] Surg Neurol. 1990 Nov;34(5):336-42 [2218855.001]
  • [Cites] Neurosurgery. 1994 Oct;35(4):615-20; discussion 620-1 [7528902.001]
  • [Cites] Cancer. 1988 Sep 1;62(5):985-8 [3409178.001]
  • [Cites] Br J Neurosurg. 1995;9(3):391-401 [7546360.001]
  • [Cites] Science. 1991 Jul 5;253(5015):49-53 [1905840.001]
  • [Cites] Pediatr Surg Int. 1997;12(1):24-7 [9035204.001]
  • [Cites] J Neurosurg. 1991 Apr;74(4):545-51 [1848284.001]
  • [Cites] Radiology. 2001 Feb;218(2):452-6 [11161161.001]
  • [Cites] Childs Brain. 1977;3(4):230-7 [891304.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):446-55 [9046301.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Feb 1;37(3):511-5 [9112446.001]
  • [Cites] Pediatr Neurosurg. 1994;21(1):91-103; discussion 104 [7947318.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):915-23 [9276355.001]
  • [Cites] Surg Neurol. 1992 Aug;38(2):114-20 [1509343.001]
  • [Cites] Acta Neuropathol. 1973;25(4):291-306 [4356228.001]
  • [Cites] Acta Neurochir (Wien). 1980;53(1-2):87-98 [7435285.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):419-26 [9308946.001]
  • (PMID = 17187270.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


84. Prabakaran S, Senthilnathan SV, Venkatadesikalu M, Prasad N, Sridharan S: Adenocarcinoma of the colon as a second malignancy in a child. Pediatr Surg Int; 2001 Jul;17(5-6):475-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the colon as a second malignancy in a child.
  • Solid tumors as second malignancies are not common in children who have been managed for lymphoproliferative disorders.
  • We report a case of adenocarcinoma (AC) of the colon as a second malignancy in a patient who was on maintenance chemotherapy for acute lymphoblastic leukemia (ALL).
  • In children, primary AC of the colon is very rare; colonic AC occurring as a second malignancy in a child is rarer still.
  • A case of AC of the colon following chemotherapy for ALL has not yet been published.
  • [MeSH-major] Adenocarcinoma. Colonic Neoplasms. Neoplasms, Second Primary. Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Fatal Outcome. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11527196.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


85. Barredo JC, Devidas M, Lauer SJ, Billett A, Marymont M, Pullen J, Camitta B, Winick N, Carroll W, Ritchey AK: Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study. J Clin Oncol; 2006 Jul 1;24(19):3142-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study.
  • This study intensified systemic therapy by delaying CNS radiation for 12 months and tailored CNS radiation by CR1 duration.
  • PATIENTS AND METHODS: Seventy-six children with first isolated CNS relapse of ALL were treated with systemic chemotherapy that effectively penetrates into the CSF and intrathecal chemotherapy for 12 months.
  • Patients with CR1 of less than 18 months received craniospinal radiation (24 Gy cranial/15 Gy spinal), whereas those with CR1 of 18 months or more received cranial radiation only (18 Gy), followed by maintenance chemotherapy.
  • Additionally, asymptomatic patients were enrolled in a thiotepa up-front therapeutic window.
  • RESULTS: Seventy-four (97.4%) of 76 eligible patients achieved a second remission.
  • Most relapses involved the bone marrow, and three second malignancies were reported.
  • CONCLUSION: Twelve months of intensive systemic chemotherapy with reduced dose cranial radiation (18 Gy) is highly effective for children with isolated CNS relapse and CR1 of 18 months or more.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / radiotherapy. Cranial Irradiation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Infant. Male. Survival Analysis. Treatment Outcome


86. Molica S: Second neoplasms in chronic lymphocytic leukemia: incidence and pathogenesis with emphasis on the role of different therapies. Leuk Lymphoma; 2005 Jan;46(1):49-54
Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second neoplasms in chronic lymphocytic leukemia: incidence and pathogenesis with emphasis on the role of different therapies.
  • Several surveys have defined chronic lymphocytic leukemia (CLL) patients as a high-risk patient population for developing second neoplasms.
  • As possible mechanisms underlying the increased risk of specific second malignancies in CLL patients the immunodeficiency associated with disease is generally proposed.
  • As far as secondary acute leukemia is concerned, greater insight into the molecular pathogenesis of therapy-related acute myeloid leukemia (AML) developing in CLL would allow to avoid treatment regimens that can lead to this complication.
  • Richter's syndrome continues to be a fatal and highly refractory to chemotherapy disease complicating the clinical course of CLL.
  • Therefore, experimental approaches of therapy should be considered in its treatment.
  • Given the prolonged survival of patients with CLL, it is important to recognize early a second cancer especially whether new symptoms or physical findings arise.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / complications. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Neoplasms, Second Primary / complications. Neoplasms, Second Primary / therapy
  • [MeSH-minor] Humans. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621780.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 44
  •  go-up   go-down


87. Lee SH, Yoo KH, Sung KW, Kim JY, Cho EJ, Koo HH, Chung SE, Kang SW, Oh SY, Ham DI, Kim YD: Tandem high-dose chemotherapy and autologous stem cell rescue in children with bilateral advanced retinoblastoma. Bone Marrow Transplant; 2008 Sep;42(6):385-91
Genetic Alliance. consumer health - Retinoblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tandem high-dose chemotherapy and autologous stem cell rescue in children with bilateral advanced retinoblastoma.
  • Although external-beam radiation therapy (EBRT) has been an effective treatment modality in patients with bilateral advanced retinoblastoma, it significantly increases the risk of second malignancies and facial deformities.
  • This study aimed to evaluate the efficacy of tandem high-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR) for treatment, instead of EBRT, in children with bilateral advanced retinoblastoma.
  • Fourteen patients with bilateral retinoblastoma received chemotherapy, and local therapy was provided whenever possible.
  • When at least one functional eye could not be saved by chemoreduction and local therapy, tandem HDCT/ASCR was provided to avoid EBRT.
  • No second malignancy has developed to date.
  • HDCT/ASCR might be an effective treatment for bilateral advanced retinoblastoma, especially in cases in which at least one functional eye could not be preserved with chemoreduction and local therapy alone, and where EBRT was unavoidable.
  • Long-term follow-up and further studies are needed to evaluate the efficacy and toxicity of HDCT/ASCR as an alternative treatment to EBRT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Peripheral Blood Stem Cell Transplantation. Retinoblastoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18574441.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  •  go-up   go-down


88. Grundy RG, Wilne SH, Robinson KJ, Ironside JW, Cox T, Chong WK, Michalski A, Campbell RH, Bailey CC, Thorp N, Pizer B, Punt J, Walker DA, Ellison DW, Machin D, Children's Cancer and Leukaemia Group (formerly UKCCSG) Brain Tumour Committee: Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/SIOP CNS 9204 trial. Eur J Cancer; 2010 Jan;46(1):120-33
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/SIOP CNS 9204 trial.
  • BACKGROUND: Radiotherapy is an effective adjuvant treatment for brain tumours arising in very young children, but it has the potential to damage the child's developing nervous system at a crucial time - with a resultant reduction in IQ leading to cognitive impairment, associated endocrinopathy and risk of second malignancy.
  • We aimed to assess the role of a primary chemotherapy strategy in avoiding or delaying radiotherapy in children younger than 3 years with malignant brain tumours other than ependymoma, the results of which have already been published.
  • Following maximal surgical resection, chemotherapy was delivered every 14 d for 1 year or until disease progression.
  • FINDINGS: Over all diagnostic groups the cumulative progression rate was 80.9% at 5 years while the corresponding need-for-radiotherapy rate for progression was 54.6%, but both rates varied by tumour type.
  • There was no clear relationship between chemotherapy dose intensity and outcome.
  • Patients with medulloblastoma presented as a high-risk group, 83.9% having residual disease and/or metastases at diagnosis.
  • This treatment strategy was less effective for AT/RT with 3-year OS of 16.7% (CI: 0.8-51.7) and CNS PNET with 1-year OS of 9.1% (CI: 0.5-33.3).
  • INTERPRETATION: The outcome for very young children with brain tumours is dictated by degree of surgical resection and histological tumour type and underlying biology as an indicator of treatment sensitivity.
  • Desmoplastic/nodular sub-type of medulloblastoma has a better prognosis than classic histology, despite traditional adverse clinical features of metastatic disease and incomplete surgical resection.
  • This study highlights the differing therapeutic challenges presented by the malignant brain tumours of early childhood, the importance of surgical approaches and the need to explore individualised brain sparing approaches to the range of malignant brain tumours that present in early childhood.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy
  • [MeSH-minor] Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Astrocytoma / surgery. Child, Preschool. Choroid Plexus Neoplasms / drug therapy. Choroid Plexus Neoplasms / radiotherapy. Choroid Plexus Neoplasms / surgery. Disease Progression. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infant. Male. Medulloblastoma / drug therapy. Medulloblastoma / radiotherapy. Medulloblastoma / surgery. Neuroectodermal Tumors, Primitive / drug therapy. Neuroectodermal Tumors, Primitive / radiotherapy. Neuroectodermal Tumors, Primitive / surgery. Radiotherapy, Adjuvant / methods. Survival Analysis. Teratoma / drug therapy. Teratoma / radiotherapy. Teratoma / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19818598.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


89. Laccourreye O, Veivers D, Bassot V, Ménard M, Brasnu D, Laccourreye H: Analysis of local recurrence in patients with selected T1-3N0M0 squamous cell carcinoma of the true vocal cord managed with a platinum-based chemotherapy-alone regimen for cure. Ann Otol Rhinol Laryngol; 2002 Apr;111(4):315-21; discussion 321-2
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of local recurrence in patients with selected T1-3N0M0 squamous cell carcinoma of the true vocal cord managed with a platinum-based chemotherapy-alone regimen for cure.
  • Based on an inception cohort of 35 patients with T1-3N0M0 squamous cell carcinoma of the true vocal cord who had a complete clinical response after a platinum-based induction chemotherapy regimen and a minimum of 3 years of follow-up, the current retrospective study documented the long-term results and consequences of local recurrence following the use of a platinum-based chemotherapy-alone regimen for cure.
  • During the years 1985 to 1996, 231 patients with invasive squamous cell carcinoma of the true vocal cord classified as T1-3N0M0 were managed at our department with a platinum-based induction chemotherapy regimen.
  • Thirty-five of the 77 patients with complete clinical response were managed at our institution with a platinum-based chemotherapy-alone regimen.
  • The statistical analysis of data on survival, local control, nodal control, distant metastasis, and metachronous second primary tumor incidence was based on the Kaplan-Meier product limit method.
  • Overall, the causes of death were intercurrent disease in 6 patients and metachronous second primary tumor in 4 patients.
  • Salvage treatment in patients with local recurrence yielded a 100% local control rate and laryngeal preservation rate.
  • The 5- and 10-year actuarial estimates for patients with metachronous second primary tumor were 9.7% and 28.1%, respectively.
  • Although local recurrence was noted in almost a third of patients with complete clinical response who were managed with a platinum-based chemotherapy-alone regimen, it did not appear to be detrimental, as none of the patients who had local recurrence ultimately died from their disease or lost their larynx.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Cisplatin / therapeutic use. Laryngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local. Vocal Cords
  • [MeSH-minor] Actuarial Analysis. Adult. Aged. Chi-Square Distribution. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Otol Rhinol Laryngol. 2002 Sep;111(9):860 [12296346.001]
  • (PMID = 11991582.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


90. Mudie NY, Swerdlow AJ, Higgins CD, Smith P, Qiao Z, Hancock BW, Hoskin PJ, Linch DC: Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study. J Clin Oncol; 2006 Apr 1;24(10):1568-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study.
  • PURPOSE: To assess long-term site-specific risks of second malignancy following non-Hodgkin's lymphoma (NHL) in relation to treatment and demographic factors.
  • PATIENTS AND METHODS: A cohort of 2,456 patients with NHL who were first treated from 1973 to 2000 and were younger than 60 years from centers in the British National Lymphoma Investigation were observed, and occurrences of second malignancy was compared with expectations based on general population cancer rates in England and Wales.
  • RESULTS: In total, 123 second malignancies occurred.
  • Relative risks (RRs) were significantly elevated for all malignancies combined (RR = 1.3; 95% CI, 1.1 to 1.6) and for leukemia (RR = 8.8; 95% CI, 5.1 to 14.1) and lung cancer (RR = 1.6; 95% CI, 1.1 to 2.3).
  • RRs of malignancy overall diminished significantly with increasing age at first treatment.
  • Leukemia risk was significantly increased after chemotherapy (RR = 10.5; 95% CI, 5.0 to 19.3) and mixed-modality treatment (RR = 13.0; 95% CI, 5.2 to 26.7).
  • Relative risks of lung (RR = 1.9; 95% CI, 1.1 to 3.1) and colorectal (RR = 2.1; 95% CI, 1.1 to 3.6) cancers were significantly raised following chemotherapy.
  • CONCLUSION: NHL patients are at elevated risk of developing second malignancy, particularly leukemia and lung cancer.
  • The relative risk is greater with patients who are younger at first treatment.
  • Chemotherapy predisposes patients toan increased risk of leukemia, and possibly lung and colorectal cancers.
  • The role of specific drug treatments in the etiology of solid cancers after NHL deserves further investigation.
  • [MeSH-major] Lymphoma, Non-Hodgkin / complications. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adolescent. Adult. Breast Neoplasms / etiology. Child. Child, Preschool. Cohort Studies. Colorectal Neoplasms / etiology. Female. Humans. Lung Neoplasms / etiology. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16520465.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


91. von Ostau C, Krege S, Hartmann M, Rübben H: Metachronous contralateral germ cell tumor 7 years after management of testicular intraepithelial neoplasia by chemotherapy and multiple control biopsies. Scand J Urol Nephrol; 2001 Oct;35(5):430-1
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous contralateral germ cell tumor 7 years after management of testicular intraepithelial neoplasia by chemotherapy and multiple control biopsies.
  • We report about a metachronous germ cell tumor 7 years after chemotherapy of advanced testicular cancer and contralateral testicular intraepithelial neoplasia (TIN).
  • Chemotherapy can not safely eradicate TIN.
  • The safest treatment for TIN remains low dose radiation.
  • [MeSH-major] Carcinoma in Situ / therapy. Neoplasms, Germ Cell and Embryonal / therapy. Neoplasms, Second Primary / diagnosis. Testicular Neoplasms / therapy. Testis / pathology
  • [MeSH-minor] Adult. Biopsy. Humans. Male. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11771876.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


92. Ng WW, Cheung YS, Wong J, Lee KF, Lai PB: A preliminary analysis of combined liver resection with new chemotherapy for synchronous and metachronous colorectal liver metastasis. Asian J Surg; 2009 Oct;32(4):189-97
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A preliminary analysis of combined liver resection with new chemotherapy for synchronous and metachronous colorectal liver metastasis.
  • OBJECTIVE: To compare the survival between patients with synchronous and metachronous colorectal liver metastases after hepatectomy with new generation of peri-operative chemotherapy.
  • METHODS: From October 2002 to January 2008, patients receiving hepatectomy for synchronous or metachronous colorectal liver metastasis were studied retrospectively.
  • RESULTS: Fifty-five patients (synchronous group=35, metachronous group=20) underwent hepatectomy for colorectal liver metastases.
  • They had received less hepatic curative hepatectomy (81.1% vs. 100%) with a higher rate of peri-operative chemotherapy (91.4% vs. 50%) and postoperative morbidity (25.7% vs. 0%).
  • However both groups had no statistical significant difference in median overall survival (OS) and disease free survival (DFS).
  • Inferior OS and DFS were observed in the synchronous group for patients who had no peri-operative chemotherapy or those showing poor response to chemotherapy.
  • CONCLUSION: Synchronous colorectal liver metastasis is not a poor prognostic factor for survival when compared with the metachronous metastasis.
  • Globally curative hepatectomy in combination of new generation of chemotherapy is recommended for the management of resectable colorectal liver metastasis.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19892621.001).
  • [ISSN] 0219-3108
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


93. Radaelli F, Onida F, Rossi FG, Zilioli VR, Colombi M, Usardi P, Calori R, Zanella A: Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution. Hematology; 2008 Aug;13(4):195-202
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.
  • A minority of patients undergo thrombohemorrhagic complications, which might be prevented by cytoreductive treatment in high risk categories.
  • In this study, we retrospectively investigated long-term development of hematological and non-hematological second malignancies in 331 patients with ET, analyzing possible associations with chemotherapy treatments.
  • Of the 194 patients who were treated with chemotherapy, 116 (60%) received only HU, 38 (19.5%) only ALK (busulfan or melphalan) and 40 (20.5%) ALK followed by HU.
  • After a median time of 87 months from the diagnosis of ET, 43 patients developed a second malignancy, hematological in 15 and non-hematological in 28, for an overall cumulative incidence of 13%.
  • According to the type of treatment, second malignancies were documented in 11.2% of patients treated with only HU, in 26.3% of patients who received only ALK, and in 25% of those treated with ALK followed by HU.
  • Ten cases (7.3%) were recorded among the 137 patients who did not receive any treatment.
  • Our analysis revealed a significant association between treatment with alkylating agents and an increased risk of developing second hematological malignancies, whereas no such association was detected with regard to treatment with hydroxyurea single agent in our ET population.
  • In addition, different treatment strategies did not affect the risk of developing second solid cancers.
  • [MeSH-major] Alkylating Agents / adverse effects. Hematologic Neoplasms / chemically induced. Hydroxyurea / adverse effects. Neoplasms, Second Primary / chemically induced. Thrombocythemia, Essential / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Busulfan / administration & dosage. Busulfan / adverse effects. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Male. Melphalan / administration & dosage. Melphalan / adverse effects. Middle Aged. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Essential Thrombocythemia.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18796244.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkylating Agents; G1LN9045DK / Busulfan; Q41OR9510P / Melphalan; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


94. Stark B, Sharon R, Rechavi G, Attias D, Ballin A, Cividalli G, Burstein Y, Sthoeger D, Abramov A, Zaizov R: Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with non-B-cell acute lymphoblastic leukemia: the Israel National Study report. Cancer; 2000 Jan 1;88(1):205-16
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with non-B-cell acute lymphoblastic leukemia: the Israel National Study report.
  • BACKGROUND: Preventive cranial radiotherapy (CRT) in childhood acute lymphoblastic leukemia (ALL), although effective, may be associated with neurologic sequelae and second malignancies.
  • Attempts to replace CRT with intensified intrathecal therapy (IT) have shown promise in lower risk subgroups.
  • In the Israel National Study (INS) 89 trial, the efficacy of extended triple IT (TIT) alone for cranial prophylaxis in an enlarged non-high risk group (Non-HRG) was assessed in the context of a modified ALL-Berlin-Frankfurt-Munster (BFM) systemic chemotherapy program.
  • In the INS 89 protocol, all Non-HRG patients were treated with extended TIT x 18 times and systemic therapy based on the BFM 86 protocol, with the addition of etoposide x 4 times.
  • At a median follow-up of 58 months (range, 2-8.5 years), the overall 5-year event free survival (EFS) was 73.5% +/- 3% (standard error ¿SE), and the cumulative central nervous system (CNS) recurrence rate was 4.3% +/- 1.4% (SE) (isolated, 2.3%; combined, 2%).
  • Of the 220 eligible children, 189 (86%) were in the Non-HRG group, and their 5-year EFS was 77.8% +/- 3% (SE).
  • The cumulative CNS recurrence rate for patients without CNS disease at presentation was 3.1% +/- 1% (SE) (isolated, 1.7%; combined, 1.4%).
  • Within the risk subsets defined by the BFM 86 of the Non-HRG, the 5-year EFS rates of the RG (148 patients) and the SRG (41 patients) were 74.8% +/- 4% (SE) and 89.5% +/- 5% (SE), respectively, and the rates of CNS recurrence (isolated and combined) were 4% and 0%, respectively.
  • For the HRG (31 patients), the 5-year EFS and CNS recurrence rates were 47.9% +/- 9% (SE) and 8.
  • 5% +/- 6% (SE), respectively.
  • CONCLUSIONS: Early extended TIT therapy in the context of modified BFM 86 systemic chemotherapy was found to provide adequate CNS protection and systemic leukemia control in patients with non-high risk ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / prevention & control. Central Nervous System Neoplasms / secondary. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Chemotherapy, Adjuvant. Child. Child, Preschool. Cytarabine / administration & dosage. Female. Humans. Hydrocortisone / administration & dosage. Infant. Injections, Spinal. Israel. Life Tables. Male. Methotrexate / administration & dosage. Radiotherapy, Adjuvant. Risk. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Non Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10618625.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


95. Prall F, Ostwald C, Schiffmann L, Barten M: Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma? Oncol Rep; 2007 Jul;18(1):203-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma?
  • Since 5-fluorouracil (5-FU)-based chemotherapy has become standard adjuvant treatment for patients with node-positive colonic adenocarcinoma, there has arisen the need for predictive factors.
  • All patients with a single, non-metachronous node-positive colonic adenocarcinoma who underwent a potentially curative resection at this institution in the years 1994-2002, and who received adjuvant 5-FU (n=95) were included in this study.
  • However, by careful histopathological examination a high-risk group of node-positive patients can be defined that could be candidates for studies of alternative (more aggressive) adjuvant treatment.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacology. Antimetabolites, Antineoplastic / therapeutic use. Colonic Neoplasms / drug therapy. Colonic Neoplasms / genetics. Fluorouracil / therapeutic use. Polymorphism, Single Nucleotide. Promoter Regions, Genetic / genetics. Thymidylate Synthase / genetics
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Adult. Aged. Aged, 80 and over. Disease Progression. Drug Resistance, Neoplasm. Female. Genotype. Humans. Male. Middle Aged. Polymerase Chain Reaction. Retrospective Studies. Survival Rate

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549369.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  •  go-up   go-down


96. Swerdlow AJ, Barber JA, Hudson GV, Cunningham D, Gupta RK, Hancock BW, Horwich A, Lister TA, Linch DC: Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol; 2000 Feb;18(3):498-509
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment.
  • PURPOSE: To assess long-term site-specific risks of second malignancy after Hodgkin's disease in relation to age at treatment and other factors.
  • PATIENTS AND METHODS: A cohort of 5,519 British patients with Hodgkin's disease treated during 1963 through 1993 was assembled and followed-up for second malignancy and mortality.
  • RESULTS: Three hundred twenty-two second malignancies occurred.
  • Relative risks of gastrointestinal, lung, breast, and bone and soft tissue cancers, and of leukemia, increased significantly with younger age at first treatment.
  • Gastrointestinal cancer risk was greatest after mixed-modality treatment (relative risk [RR] = 3.3; 95% confidence interval [CI], 2.1 to 4.8); lung cancer risks were significantly increased after chemotherapy (RR = 3.
  • 3; 95% CI, 2.4 to 4.7), mixed-modality treatment (RR = 4.3; 95% CI, 2.9 to 6.2), and radiotherapy (RR = 2.9; 95% CI, 1.9 to 4.1); breast cancer risk was increased only after radiotherapy without chemotherapy (RR = 2.5; 95% CI, 1.4 to 4.0); and leukemia risk was significantly increased after chemotherapy (RR = 31.6; 95% CI, 19.7 to 47.6) and mixed-modality treatment (RR = 38.1; 95% CI, 24.6 to 55. 9).
  • These risks were generally greater after treatment at younger ages: for patients treated at ages younger than 25 years, there were RRs of 18.7 (95% CI, 5.8 to 43.5) for gastrointestinal cancer after mixed-modality treatment, 14.4 (95% CI, 5.7 to 29.3) for breast cancer after radiotherapy, and 85.2 (95% CI, 45.3 to 145.7) for leukemia after chemotherapy (with or without radiotherapy).
  • CONCLUSION: Age at treatment has a major effect on risk of second malignancy after Hodgkin's disease.
  • Although absolute excess risks are greater for older patients, RRs of several important malignancies are much greater for patients who are treated when young.
  • The increased risk of gastrointestinal cancers may relate particularly to mixed-modality treatment, and that of lung cancer to chemotherapy as well as radiotherapy; there are also well-known increased risks of breast cancer from radiotherapy and leukemia from chemotherapy.
  • The roles of specific chemotherapeutic agents in the etiology of solid cancers after Hodgkin's disease require detailed investigation.
  • [MeSH-major] Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Cohort Studies. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Risk Factors. Time Factors. United Kingdom / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10653865.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


97. Garaventa A, Gambini C, Villavecchia G, Di Cataldo A, Bertolazzi L, Pizzitola MR, De Bernardi B, Haupt R: Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine. Cancer; 2003 Mar 1;97(5):1332-8
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine.
  • Radiotherapy may provide additional benefits in the treatment of NB, with moderate side effects such as hematologic and thyroid toxicity.
  • We describe our experience with second cancers occurring in children treated with (131)I-MIBG and chemotherapy.
  • METHODS: The clinical records of 119 consecutive NB cases treated with (131)I-MIBG at a single institution between 1984 and 2001 were reviewed for the occurrence of a second malignant neoplasm (SMN).
  • The schwannoma and the rhabdomyosarcoma developed within the residual neuroblastic mass after first-line therapy.
  • CONCLUSIONS: Should (131)I-MIBG treatment become more broadly employed in the therapeutic strategy for neuroblastoma, the risk of second cancer will have to be taken into consideration.
  • The organization of an international registry of subjects treated with (131)I-MIBG might better define the frequency and features of second malignancies following this radiometabolic approach.
  • [MeSH-major] 3-Iodobenzylguanidine / therapeutic use. Neoplasms, Radiation-Induced. Neoplasms, Second Primary. Neuroblastoma / radiotherapy. Peripheral Nervous System Neoplasms / radiotherapy. Radiopharmaceuticals / therapeutic use
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Hypothyroidism / etiology. Infant. Male. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • (PMID = 12599242.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 35MRW7B4AD / 3-Iodobenzylguanidine
  •  go-up   go-down


98. Djeridane M, Oudard S, Escoffre-Barbe M, Lacotte-Thierry L, Desablens B, Briére J, Dib M, Cassasus P, Ghandour C, Lamy T, Lejeune F, Simon M, Traullé C, Vigier M, Maisonneuve H, Briére J, Colonna P, Andrieu JM: Treatment of patients with advanced or bulky Hodgkin disease with a 12-week doxorubicin, bleomycin, vinblastine, and dacarbazine-like chemotherapy regimen followed by extended-field, full-dose radiotherapy: long-term results of the Groupe Ouest et Est des Leucémies et Autres Maladies de Sang H90-A/B Multicenter Randomized Trial. Cancer; 2002 Nov 15;95(10):2169-79
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of patients with advanced or bulky Hodgkin disease with a 12-week doxorubicin, bleomycin, vinblastine, and dacarbazine-like chemotherapy regimen followed by extended-field, full-dose radiotherapy: long-term results of the Groupe Ouest et Est des Leucémies et Autres Maladies de Sang H90-A/B Multicenter Randomized Trial.
  • BACKGROUND: This Phase II study was performed in patients with advanced or bulky Hodgkin disease (HD) to evaluate the results of a 7-drug chemotherapy (CT) regimen that was administered over 12 weeks according to 2 randomized modalities followed by high-dose lymph node irradiation.
  • METHODS: From 1990 to 1996, 162 patients with HD at clinical stages (CS) I-III with bulky disease (mediastinal mass ratio >or= 0.45 and/or unilateral or bilateral pelvic plus lumboaortic disease; 86 patients) or CS IV (76 patients) were randomized to receive the same cumulated dose of a CT regimen consisting of epirubicin (240 mg/m(2)), bleomycin (60 mg/m(2)), vinblastine (20 mg/m(2)), vincristine (4 mg/m(2)), cyclophosphamide (4000 mg/m(2)), etoposide (900 mg/m(2)), and methotrexate (180 mg/m(2)) plus methylprednisolone (1500 mg/m(2)) over 12 weeks either every 4 weeks (Arm Y, 79 patients) or every 3 weeks (Arm Z, 83 patients).
  • Patients with disease in complete remission (CR) or partial remission after CT received extended-field lymph node irradiation (involved areas, 40 grays [Gy]; noninvolved areas, 30 Gy).
  • Thirty-five patients developed recurrent disease; most of those patients were in post-CT partial remission.
  • Thirty-eight patients died: 24 patients from HD, 3 patients from CT-related early sepsis, 1 patient from radiation-induced pneumonitis, 6 patients from a second malignancy, and 4 patients from causes unrelated to treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Combined Modality Therapy. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Prospective Studies. Radiotherapy Dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 12412171.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  •  go-up   go-down


99. Seidemann K, Tiemann M, Schrappe M, Yakisan E, Simonitsch I, Janka-Schaub G, Dörffel W, Zimmermann M, Mann G, Gadner H, Parwaresch R, Riehm H, Reiter A: Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood; 2001 Jun 15;97(12):3699-706
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
  • Previous experience from NHL-Berlin-Frankfurt-Münster (BFM) trials indicated that the short-pulse B-NHL-type treatment strategy may also be efficacious for ALCL.
  • The purpose of this study was to test the efficacy of this protocol for treatment of childhood ALCL in a large prospective multicenter trial and to define risk factors.
  • Extranodal manifestations were as follows: mediastinum, n = 28; lung, n = 13; skin, n = 16; soft tissue, n = 13; bone, n = 14; central nervous system, n = 1; bone marrow, n = 5.
  • After a cytoreductive prephase, treatment was stratified into 3 branches: patients in K1 (stage I and II resected) received three 5-day courses (methotrexate [MTX] 0.5 g/m(2), dexamethasone, oxazaphorins, etoposide, cytarabine, doxorubicin, and intrathecal therapy); patients in K2 (stage II nonresected and stage III) received 6 courses; patients in K3 (stage IV or multifocal bone disease) received 6 intensified courses including MTX 5 g/m(2), high-dose cytarabine/etoposide.
  • Events were as follows: progression during therapy, n = 2; progression or relapse after therapy, n = 20; second malignancy, n = 1.
  • It was concluded that short-pulse chemotherapy, stratified according to stage, is effective treatment for pediatric ALCL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Large-Cell, Anaplastic / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Germany. Humans. Immunophenotyping. Infant. Lymphoma, B-Cell / drug therapy. Male. Prospective Studies. Protein-Tyrosine Kinases / metabolism. Receptor Protein-Tyrosine Kinases. Recurrence. Risk Factors. Treatment Failure


100. Robak T, Blonski JZ, Gora-Tybor J, Kasznicki M, Konopka L, Ceglarek B, Komarnicki M, Lewandowski K, Hellmann A, Lewandowski K, Moskwa A, Dmoszyńska A, Sokołowska B, Dwilewicz-Trojaczek A, Tomaszewska A, Sułek K, Całbecka M: Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine. Eur J Cancer; 2004 Feb;40(3):383-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine.
  • The increased frequency of second malignancies in chronic lymphocytic leukaemia (CLL) is well known.
  • Moreover, antineoplastic therapy additionally increases the risk of secondary cancers.
  • In this study, we analysed whether treatment with cladribine (2-chlorodeoxyadenosine, 2-CdA) during the course of CLL had an impact on the subsequent occurrence of either secondary solid tumours or Richter's syndrome.
  • Median time from the start of CLL treatment to the diagnosis of secondary malignancy was 1.9 years (0.5-5.1 years) for the 2-CdA group, 1.8 years (0.3-7.9 years) for the AA group and 3.9 years (0.3-8.4 years) for the 2-CdA+AA group.
  • A total of 68 malignancies were reported in 65 patients.
  • In the group of patients treated with 2-CdA alone, there were 15 (6.0%) cases, in the group of patients treated with AA alone there were 26 (2.8%) cases, and in the group treated with 2-CdA+AA there were 17 (5.3%) cases of secondary malignancies.
  • The differences between the frequency of secondary malignancies in the 2-CdA and 2-CdA+AA versus AA alone groups were not significant (P=0.05 and P=0.06, respectively).
  • In conclusion, 2-CdA in CLL patients does not seem to increase the risk of secondary malignancies except for lung cancers.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cladribine / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lung Neoplasms / drug therapy. Neoplasms, Second Primary / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Retrospective Studies. Syndrome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14746857.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 47M74X9YT5 / Cladribine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down






Advertisement